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Viruses represent some of the smallest biological structures. They consist of a protein 
coating surrounding an inner core of nucleic acids which carry all of the information 
required for their replication. Broadly speaking, there are two classes of viruses: the DNA 
viruses in which the nucleic acid is DNA (such as the herpes viruses) and the RNA viruses 
in which the genetic material is RNA (such as the flu virus).39 Retroviruses carry an 
enzyme, called reverse transcriptase, which catalyzes transcription of viral RNA into 
double-helical DNA which then integrates into the genome of the infected cell where it is 
known as a provirus. 37 The human immune deficiency virus (HIV) is a retrovirus of the 
lentivirus family, and two genetically distinct subtypes, HIV -1 and HIV -2, have been 
characterized. HIV has been identified as the etiological agent of the acquired immune 
deficiency syndrome (AIDS),37 and the pathological outcome of infection with HIV is 
depletion of the T4 lymphocyte population. Consequently, AIDS is characterized by 
severe infection with opportunistic organisms, resulting from the immunodeficiency, 
which ultimately leads to death. AIDS has become the most important epidemic in modern 
times. To date, the only proven strategy for the treatment of this disease is inhibition of 
viral replication, particularly inhibition of the human immune deficiency virus (HIV) 
reverse transcriptase. 38 The reason for the apparent lack of progress in antiviral therapy, 
as compared with the field of antibacterials, has been a problem of selectivity. 
Preferentially, any drug should selectively kill pathogenic organisms in the presence of 
1 
2 
other living cells. It is thought that sufficient biochemical differences may exist between 
the metabolism of prokaryotic bacterial cells and of mammalian cells to enable selectivity to 
be achieved.39 This explains, to some degree, the early development of antibacterial 
agents which proved safe for human use.39 Viruses, on the other hand, despite their 
apparent simplicity, represent a bigger problem. This is due to their replicative cycle in 
which the viruses become physically and functionally incorporated into the host cells. 
Thus, it remains difficult to distinguish unique biochemical features suitable for selective 
attack.39 However, considerable progress has been achieved in the field of antiviral agents 
as will be shown. In this chapter, a selection of different antiviral agents will be discussed 
in terms of (1) their structural similarities or differences from the nucleosides found in the 
DNA and RNA or from a parent potent antiviral agent, (2) the mode of action as medicinal 
agents or prodrugs, and (3) the extent of selectivity and potency based upon the inhibitory 
concentrations of the agents. 
Naturally Occurring Nucleosides Antitumor 
Antibiotics 
The structure of the nucleosides found in DNA and RNA are illustrated in Table 1.82 
It can be seen that nucleosides are constituted of a nucleic acid base (pyrimidine or purine) 
and a ribose moiety (ribose or deoxyribose). The bases are adenosine (1), guanosine (2), 
cytidine (3), uridine (4), and thymidine (5). Therefore, the major modifications on 
nucleosides might then focus on two possible sites: a) the nucleic acid base, such as by 
replacment of the nitrogen atom (s) with a CH group(s) or replacing the hydrogen atom 
with another functionality; b) the ribose moiety, such as by replacment of the oxygen atom 
with a CH group or by attaching an acyclic side chain in place of the cyclic sugar moiety. 
In many cases, both modifications have been employed for maximum activity as will be 
discussed.18-44 
Some 60-70 naturally occurring nucleoside analogs have been widely used as bio-
3 
TABLE I 
COMMON BASES AND NUCLEOSIDES 
Compd Structure Base Nucleoside 
X=H X =ribose 




H:r ' ~ N 
2 N I ~ Guanine Guanosine 






















chemical probes for many complex cellular reactions.71 Nucleoside analogs of adenosine 
in which N-7 of the imidazole ring of the purine system has been replaced by a carbon 
, atom were isolated as natural products.72 For example, tubercidine (6), toyocamycin (7), 
sangivamycin (8), and cadeguomycin (9) have stimulated considerable interest because 
they are powerful antibacterial, antifungal, and cytotoxic agents. They have also found use 
against some forms of human cancer, such as in the treatment of cutaneous neoplasms. 71 
HO 
6, R = H 
7, R = CN 
OH 
8, R = C(O)NH2 
HO 
HO 
Nucleoside Analo~s as Antitumor 
Antiviral Ai:ents 
HO 
OH HO OH 
9 10 
After the discovery that a few naturally occurring nucleoside antitumor antibiotics were 
derivatives of pyrrolo[2,3-d]pyrimidine, several related deazapurine nucleosides were 
synthesized. One example that clearly illustrates the type of modifications made on the 
parent compounds is the 3,7-dideazaadenosine (10). Two nitrogen atoms were replaced 
by CH groups in the purine structure. Nucleoside 10 showed significant activity against 
P388 leukemia in cell culture, with an inhibitory dose (IDso) value of 7.2 J.LM.18 
However, Tubercidine (6) was found to be active at an even lower concentration (IDso = 
3.8 J.LM).18 
5 
One of the most important antiviral drugs discovered over the past few years is the 
acyclic analog of guanosine, {9-[(2-hydroxyethoxy)methylguanine] (acyclovir, 11)}.63 
This compound potently and selectively inhibits the in vitro and in vivo replication of 
herpes simplex viruses.26 Acyclovir has been used clinically for the treatment of certain 
herpes virus infections. 53 The biochemical basis for the antiviral activity of acyclovir (11) 
Acyclovir, 11 12 R=Ac 
13 R=H 
is believed to involve its specific phosphorylation to the corresponding monophosphate by 
the viral enzyme thymidine kinase. The monophospate is phosphorylated further by 
cellular kinases to acyclovir triphosphate, SO a potent and selective inhibitor of the virus-
encoded DNA polymers. This terminates viral replication. The success of acyclovir as an 
antiviral drug has prompted several groups to prepare and evaluate many structurally 
related acyclic analogs.54 Two examples 12 and 13 are the deaza-chloro analogs of 
acyclovir. Both compounds were more active than acyclovir against human 
cytomegalovirus (HCMU), but both were inactive against herpes simplex virus type 1 
(HSV-1).63 
Another family of nucleoside analogues was studied after the synthesis of the 
carbocyclic adenosine [(±)-aristeromycin] (14) was reported.66 Neplanocin A (15), an 
unsaturated analog of 14, has generated considerable attention both synthetically and 
biologically because of the effect of the double bond on the activity and potency.48 











Neplanocin A (15) 
6 
L1210, and it also has broad antiviral activity.65 The biological activity of neplanocin A 
(15) is attributed to its powerful ability to inhibit S-adenosylhomocysteine (AdoHcy) 
hydrolase.9 AdoHcy hydrolase catalyzes the reversible hydrolysis of AdoHcy to 
adenosine and homocysteine through a mechanism involving the oxidation of the 3'-
hydroxyl group of the substrate.55,56 On this basis, AdoHcy hydrolase has become a 
target for the design of antiviral agents for the following reasons. 85 Most plant and animal 
viruses require a methylated cap structure at the 5'-tenninus of their mRNA for viral 
replication) Virus encoded methyl-transferases that are involved in the formation of this 
methylated cap structure are inhibited by AdoHcy.57 Undermethylation of the viral mRNA 
cap structure induced by the inhibition of Ado Hey hydrolase has been correlated with the 
inhibition of viral replication. 58 A close correlation exists between the antiviral potency of 
adenosine analogs and their inhibitory effects on AdoHcy hydrolase.16 A close correlation 
also exists between the antiviral potency of carbocyclic nucleosides and their ability to 
elevate cellular levels of AdoHcy.62 An example of an analog of carbocyclic adenosine 
that showed promising antiviral activity included the 3-deazoneplanocin A (16).19 Triol 
16 exhibited excellent antiviral activity against vesicular stomatitis (IDso = 0.3 J..Lg/mL) and 
against vaccinia (IDso = 0.3 J..Lg/mL). The acyclic analogue 17 showed antiviral activity 
(ICso = 70 JlM) but was less than that observed for neplanocin A (15, ICso = 0.08 JlM).9 









16 17 CPE-C (18) 
tumors.48 The latter compound also exhibited good activity against DNA viruses (HSV -1, 
HSV -2) and against RNA viruses (vesicular stomatitis and yellow fever).48 
Thus far the only approved drug by the FDA for the treatment of HIV infected patients 
was 3'-azido-3'-deoxythymidine (AZT, 19). At the present time, AZT is the most 
successful agent used for the treatment of AIDS patients. 83 Originally, AZT was 
synthesized by Horwitz and co-workers from thymidine.36 Since the initial work, AZT 
has been studied extensively in view of its potent HIV inhibitory activity and clinical 
efficacy. In general, the mechanism of action of AZT has been reported to be similar to 
that found for acyclovir (11) in that the viral kinases convert AZT to its monophospate and 
cellular kinases convert the monophosphate to the corresponding triphosphate 20.28 At 
therapeutic doses of 19, the triphosphate metabolite 20 selectively inactivates the reverse 
transcriptase of HN while leaving cellular pol ymerases relatively unaffected. 85 It has been 
suggested that the charge distribution in the azido group (-N=N-N+) might mimic the 
charge distribution in the pJ;10sphate group (O--P(0)02-) of a nucleotide},ll Moreover, 
this N3· group is accommodated at the nucleotide binding site present in reverse 
trancriptase. 73 As a result of the success of AZT as an antiviral agent, many analogs of 
AZT have been prepared.14 Two examples of such analogs which showed strong antiviral 
activity are the deoxyuridine analog 21a-b and the deoxycytidine analogs 22a-b. The 
8 
0 0 0 
HO 
II II II 
0-~-o-~ -0-~-0 
OH OH OH 
AZf (19) AZf Triphosphate (20) 
antiviral activity of these compounds, compared to that observed for AZT, is illustrated in 
Table II. 
Another modification on AZT was carried out in which a cyano (CN) group was 
introduced in place of the azido group on the basis of the electronic similarities (inductive 
effect F values: CN = 0.51; OH = 0.29; N3 = 0.3; these values could also be refered to as 
field effect values which are a component of the substituent effects calculated from the 
Hammett equation)74 and similarities in steric bulk. However, the cyano analogue 23 was 
shown to be inactive as an antiviral agent. 30 AZf decreased the mortality and frequency of 
opportunistic infections in a selected group of individuals with AIDS and/or AIDS-related 
complex (ARC).9 However, AZf has shown serious side effects such as suppression of 
bone marrow cell growth, combined with the appearance of AZf -resistant HIV variants. 88 
For example, Richman and co-workers60 demonstrated that because of drug-associated 
hematological abnormalities, 21% of patients undergoing AZf therapy require multiple 
blood transfusions during the 6-month treatment period. 
Certain dideoxynucleosides exhibit potent antiviral activities against HIV in vitro. 
2',3'-Dideoxyguanosine (DzG, 24a), 2',3'-dideoxyadenosine (DzA, 24b), 2',3'-di-
deoxyinosine (D2I, 24c), and N6-methyl-2',3'-dideoxyadenosine (24d) are currently 
undergoing clinical trials in patients with AIDS.15 Table III15 shows the antiviral activity 
TABLE II 
ANTIVIRAL ACTIVITY OF AZf AND ANALOGS 
R" 
R' 
Compd R R' R" X ECso,a J.LM ICso,b J.LM 
19 (AZT) CH3 N3 OH 0 0.002-0.009 200 
21a H N3 OH 0 0.18-0.46 1000 
2lb CzHs N3 OH 0 0.056-1.00 1000 
22a H N3 OH NH 0.66-1.19 >400 
22b CH3 N3 OH NH 0.081-0.22 >200 
aMedian effective concentration (antiviral effect) on day 5 after infection. 






MEDIAN EFFECTIVE (EC50) AND INHffiiTORY (IC50) 
CONCENTRATIONS OF 24a-d IN PBM CELLS15 
Compd X 
24a (DzG) OH 
24b (DzA) NHz 











aMedian effective concentration in PBM cells. 
bMedian inhibitory concentration in PBM cells. 






activity and cytotoxicity of the above dideoxy nucleosides in human peripheral blood 
mononuclear (PBM) cells. 
From this series of dideoxy nucleosides, Dzl (24c) (currently known as DDI) has 
emerged as a powerful antiviral agent, more specifically an HIV inhibitor.87 Very 
recently, DDI was approved by the FDA as a drug for the treatment of AIDS patients, 
making this compound the second approved drug for the treatment of AIDS after AZT. It 
was found that DDI is less toxic than AZT,87 and that the proposed mechanism of action is 
similar to that found for AZT and acyclovir. This reduced toxicity suggests that DDI (24c) 
is more selective than AZT in the inhibition of HIV reverse transcriptase. 
11 
Recently, a novel 6-substituted acyclouridine derivative was reported75 as a potent 
anti-HIV-1 agent in various T4 cell cultures. 1-[(2-Hydroxyethoxy)methyl]-6-
(phenylthio)thymine (HEPT, 25) appeared to be as active and selective as DDI (24c) 
against HIV -1 replication in vitro. HEPT is interesting in that it is only inhibitory to HIV-
1, and its triphosphate does not interact with HIV-1 reverse transcriptase.51 Table IV 
shows the antiviral activity and the cytotoxic concentration of HEPT compared to AZT 
(19) and DDI (24c). An extremely interesting family of HEPT analogs has been 
synthesized and evaluated for their anti HIV-1 activity. 51 This family of 6-substituted 
acyclouridines 26-31 (Table V) are somewhat novel for the following reasons. None of 
these analogues has a hydroxyl group in any position, which subsequently means that 
these compounds cannot be phosphorylated. Phosphorylation of a hydroxyl group by 
viral kinases was an essential requirement for antiviral activity in all the previously 
mentioned nucleoside antiviral agents. 50, 29, 28 The activity of these analogs has also 
proven that the hydroxyl function of HEPT does not contribute to its anti-HIV -1 activity, 
which is contrary to what was believed earlier.51 Some of these compounds (31 and 32) 
are less toxic to bone marrow cells than AZT. 88 Inhibition of bone marrow cell growth is 
the major side effect of AZT. 88 Table V shows the antiviral activity of 26-32 compared to 
that of AZT (19) and HEPT (25) against HIV-1 replication in MT-4 cells. 51 
A new class of antiviral agents of the general structure 33 was reported by Kelley and 
co-workers.40 These compounds are derivatives of 9-benzylpurines and show good 
activity against rhinoviruses, which are the most important causative agents of the common 
cold.23 These particular purines represent another example of nucleoside analogs which 
do not contain a hydroxyl group in their structure (i.e., phosphorylation cannot occur). In 
addition, this family contains some of the very few nucleoside analogs which possess an 
aromatic side group. The best antiviral activity was observed for the 4-tolyl derivative 






INHIBmON OF HIV -1 AND HIV -2 REPLICATION IN MT -4 
CELLSANDPERWHERALBLOODLYMPHOCY~ 
(PBL) BY HEPT, AZT, AND DDI51 
HEPT (25) 
Virus Strain ECso,a J.1M CCso,b Jl.M 
HIV-1 HlLV-IIIs 0.0030 7.8 
HIV-2 LAV-2 0.0028 
HIV-1 H1LV-IIIs 6.3 >500 
HIV-2 LAV-2 7.2 
HIV-1 HlLV-IIIs 7.0 740 
HIV-2 LAV-2 >250 
aEffective concentration of compound required to achieve 50% protection of MT -4 
cells against the virus-induced cytopathic effect. 
bcytotoxic concentration of compound required to reduce the viability of mock-




INHffimON OF HN-1 REPLICATION IN MT-4 CELLS BY 
HEPT (25) AND RELATED COMPOUNDS51 
0 R 
HlY~ 
0 N s ~ 
R'v"oj 
Compd R R' ECso,a J!M CCso,h JlM SIC 
19 (AZT) 0.0030±0.0010 7.7+1.0 2600 
25 (HEPT) CH3 CH20H 6.5±1 >500 >77 
26 CH3 CH3 0.33+0.3 231±3 700 
27 CH3 CH2F 1.1+0.5 209±17 190 
28 CH3 CH2Cl 1.5+0.3 196±3 131 
29 CH3 CH2N3 5.8+0.1 186±17 32 
30 CH3 C6H5 0.088+0.012 95±29 1080 
31 C2H5 CH3 0.019+0.002 161±23 8500 
32 C2H5 CH3 0.0059+0.00 13 34+7 5800 
aEffective concentration of compound required to achieve 50% protection of MT-4 cells 
against the cytopathic effect of HN -1. 
bcytotoxic concentration of compound required to reduce the viability of mock-infected 
MT-4 cells by 50%. 






R = H, 3-NH2, 4-NH2, 3-Cl, 4-Cl, 4-CH3, 
3-0CH3, 4-0CH3, 3-N02> 4-N02, 
4-CN, 3-0H, 4-0H, 4-C(CH3h. 
Nucleotide Analo2s as Antiviral A2ent~ 
14 
The first acyclic nucleotide analog, namely 9-(S)-(3-hydroxy-2-phosphonylmethoxy 
propyl)adenine [(S)-HPMPA, 34], was reported by Holy and co-workers in 1986.35 This 
phosphonate contains an isosteric, isopolar phosphonomethyl ether moiety instead of the 
phosphate moiety. (S)-HPMPA exhibited exceptionally high antiviral activity as shown in 
Table VI compared to that activity for acyclovir (11).22 It was postulated that (S)-HPMPA 
was taken up by cells and phosphorylated intracellularly to a diphosphoryl derivative 
which was a selective viral DNA polymerase inhibitor.13 However, the exact mechanism 
of action of this compound remains under investigation. 
A series of analogs of (S)-HPMPA (34) was synthesized and evaluated for antiviral 
activity, including activity against HIV .13 Examples include the 9-[2-
(phosphonomethoxy)ethyl] purines (guanine, PMEG, 35; adenine, PMEA, 36) and 9-[1-
methyl-2-(phosphonomethoxy)ethyl]guanine (37). These compounds illustrate the type of 
modifications employed on the parent compound (S)-HPMP A (34), and Table VII 
contains data on antiviral activity as compared to that of acyclovir (11) and AZT 
(19).13 
It was reported68 that phosphonoacetic acid (PPA, 38) and phosphonoformic acid 
(PFA, 39) possess good antiviral activity against herpes simplex viruses type 1 (HSV-1) 
and type 2 (HSV -2). PPA (38) could not be used in humans because of its high affinity 
for bone tissue.8 In contrast, PFA has been used clinically against HSV-1 and HSV-2.44 
Compd 
TABLE VI 
ANTIVIRAL ACfiVITY OF (S)-HPMPA (34) IN 
CELL CUL TURE22 
(S)-HPMPA (34) 
ICso, a f.lg /mL 







aMedian inhibitory concentration in cell cultures. 
hHerpes simplex type-1. 
CHerpes simplex type-2. 






In later studies of these phosphorus acids, PPA (38) and PFA (39) were coupled to a 
large number of nucleosides, modified nucleosides and acyclic nucleoside analogs to give 
the corresponding phosphonoacetates and the phosphonoformates, respectively.33 
Examples of the latter products include the phosphonoacetates 40a-b, and the 
phosphonoformate 41. Most of the coupled products showed some antiviral activity 
against HSV-1 and HSV-2. It is believed that these compounds may be acting as prodrugs 
thereby releasing the antiviral agent(s) via hydrolysis.44 
TABLE VII 
ANTIVIRAL ACfiVITY OF THE ACYCLIC PHOSPHONATES 
IN TISSUE CULTURE34 
X 
:}:N ;( ~ 
0 Y J II 
(HOhJ>~O R 
IDso.a J.Lg/mL 
Compd R HSV-1 
11 (Acyclovir) 0.5 
19 (AZT) 
35 (PMEG) H 0.08 
36 (PMEA) H 21.0 
37 CH3 2.92 
aMedian inhibitory dose in tissue culture. 
bRauscher-murine leukemia virus. 
CNot tested. 
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A number of non-nucleoside inhibitors of the key viral enzyme reverse transcriptase 
have been identified. 47 One of the most selective and potent inhibitors of HIV-1 in vitro is 
R-82150 (42). More recently, the dipyrididiazepin (BI-RG-587, 43) was demonstrated to 
be a potent inhibitor of HIV -1 (ICso = 42 J.LM) in vitro with an exquisite selectivity for 
HIV -1 over HIV -2 and other retroviruses.47 The Merck compound L-697 ,639 is another 
non-nucleoside inhibitor of reverse transcriptase, and this compound is in early clinical 
trials.47 At present, no chemical structure has been provided for this compound.47 
After the identification of a virally-derived protease (which is a key enzyme required 
for the maturation and replication of HIV), a number of dipeptide isosters were synthesized 
R-82150 (42) Bl-RG-587 (43) 
18 
and evaluated for their activity against HIV. 80 Dipeptide 44 is an exellent example of a 
potent inhibitor of HIV-protease as it showed an IC 50 value of 0.3 ~M. 80 
44 
Phosohorus-Containin~: Nucleic Acids 
The only reported pseudonucleosides with an aromatic phosphorus atom in the diazole 
moiety are the systems 1-(P-D-ribofuranosyl)- [ 1 ,2,4] J..3diazophosp hol-3-carbonamid 
(45a) and its sulfur analog 45b, both of which exhibited antitumor activity against L1210 
in mice.61 No other examples were given. 
45a X= 0 
45b X= S 
Khawaja and co-workers (1979)41 reported the synthesis of three diazaphosphole 
compounds 46, 47, and 48. The latter compound, pyrimidino(4,5-d)-1,3,2-diazaphos-
phole (48), is the first and only known purine system which contains a phosphorus atom 
in the imidazole moiety. Compounds 46 and 47 are 1-deaza and 3-deaza analogs of 
purine, respectively. A general procedure was followed for the preparation of the above 
diazaphospholes in which the appropriate o-diamines were treated with triphenyl phosphite 
19 
llOOC/1 mm Hg 
46 X= CH, Y =N 
47 X=N, Y=CH 
48 X= N, Y = N 
without the use of a solvent at 110°C under reduced pressure (1 mm Hg). The products 
were characterized by IR, UV, and mass spectrometry, but no NMR data were provided. 
Upon testing the products for biological activity, only compound 48 showed antitumor 
activity against L1210 in cell culture with an ICso value of 0.4 J.1M.41 To the best of our 
knowledge, no further work has been reported on such purine analogues. However, the 
synthesis of closely related structures will be discussed. 
Autenrieth and Brolli reportedl in 1925 the synthesis of 2-phenoxy-1,3-dihydro-2H-
1,3,2-benzodiazaphosphole 2-oxide (49) by the treatment of o-phenylenediamine with 
phenyl phosphorodichloridate. Two different conditions were employed, namely via 
boiling the reagents in benzene or by fusing both compounds without solvent above 
170°C. Later, the diazaphosphole compounds 5021 and 5145 with the same 
diazaphosphole ring were prepared by the reaction of phenylphosphonic dichloride or 
H H H 
(XA o I I 0 (XN 0 '" '" N::XN'l P, P, ~ ,, 
N' OC6Hs N' C6Hs ~N N C6Hs 
I I I 
H H H 
49 50 51 
20 
phenylphosphonic diamide with the 2-phenylenediamine or the corresponding purine 
counterpart 
The hydrolysis study of 50 and 51 by the same authors revealed that both amides 
could be hydrolyzed in acidic and alkaline conditions.21, 45 Diazaphosphole 50 was 
hydrolyzed even in hot water and gave the ring-opened product 52. The facile hydrolysis 
of 50 and 51 is quite reasonable considering the general instability of five-membered 
H 0 
I II (XN-P-CJI5 (~)H 
NH 2 
52 53 
cyclic phosphorus intermediates due to the ring strain. 84 Relief of strain in the 
P(V) intermediates generated by attack of water on phosphorus in such a system as 50 or 
51 can sometimes be achieved by ring opening to give a tetracoordinated phosphorus acid 
such as 52.84 However, in fused systems like 49-51, no theoretical or thermal studies to 
refute or verify this hypothesis have been reported. 
Edmundson and co-workers (1969)25 examined the reaction of o-phenylenediamine 
with phenyl phosphorodichloridate and obtained a single product (mp 175-176.C) whose 
structure was determined to be phenyl hydrogen-N-(2-aminophenyl)phosphoramidate 
(53). It was also reported that the attempted synthesis of the benzodiazaphosphole 49 
under a variety of other conditions was unsuccessful. Edmundson suggested that the 
reaction of o-phenylenediamine with phenyl phosphorodichloridate did not give the 
diazaphosphole 49 and that the paper of Autenrieth and Brolli should be refuted. In 1973, 
Arai and co-workers43 reported the correct synthesis of 49 via the reaction of o-
phenylenediamine and phenyl phosphorodichloridate in boiling bromobenzene. It was also 
suggested by the same authors that the workup procedure of Autenrieth and Bro11i41 
21 
converted 49 to the corresponding phosphoramidate 53. Arai and co-workers performed 
a series of hydrolysis experiments in which 53 was exposed to dilute acid, water, and 
methanoi.43 They obtained the a-phenylenediamine bishydrochloride (54) and phenyl 
phosphoric acid, the hydrophosphate salt of a-phenylenediamine (55) and phenol, and the 
dil. HCI 
+ (XNH3 2Cl 
NH + 3 
54 




(X~3 - OP(O)(OCH3)0Ph 
NH2 
56 
a-phenylenediamine salt of methyl phenyl phosphate (56), respectively. 
Malavaud and co-workers46 (1979) treated tris(dimethylamino)phosphine with 2-(N-
alkylamino)aniline (57) to obtain a benzodiazaphosphole in the form of a tetramer 58. The 
monomers of this compound were isolated at room temperature as BF3 complexes 59a-b 
since the isolation of the neutral monomer was not possible. It was also postulated that 
adduct formation with BF3 occurs at theN atoms rather than at the P atom since the lone 
electron pair on the P atom was assumed to be less available. 
A similar study was carried out by Norman and co-workers6 (1989) in which they 
reported unsuccessful attempts to isolate a methyl derivative of a diazaphosphole 60 via 
crystallization and chromatographic techniques. However, it was possible to utilize 












Mo(C0)3 to form complex 61 which could be isolated 






It is appropriate to discuss briefly aromatic phosphorus amides in terms of their main 
functions in organic chemistry since a large number of related compounds are included in 
this project The vast majority of organic phosphorus amides with a coordination number 
23 
of IV possess one of the following general structures 62-65.5 These tetracoordinated 
phosphorus compounds do not display a large range of reactions useful in general organic 
62 phosphinic amide (aminophosphine oxide) 
63 phosphonic diamide (diaminophosphine oxide) 
64 phosphoramidate ester (amidophosphate) 
65 phosphorodiamidate ester ( diamidophosphate) 
synthesis, relative to such analogues as the ylides (R3P=CHR), phosphonates 
[R(RO)zP=O], and iminophosphoranes (R3P=NR).l7 Nevertheless the above amides are 
important reagents in transferring such moieties as R, X, or Y in (RX)3P=Y to non-
phosphorus-containing compounds. An example of this is the use of trialkyl phosphates 
as relatively mild N-alkylating reagents for amines.lO 
A number of aromatic phosphorus amides have been synthesized and were considered 
as protected amines, but the phosphorus-aryloxy group could be easily cleaved.78 
Preference for the use of phosphorus protecting groups stems from the fact that carboxylic 
amides are resistant to hydrolysis over high temperatures, and strongly acidic or basic 
conditions are required to effect complete hydrolysis.86 In a separate study of the 
hydrolysis of phosphorus amides, it was shown that the acid-catalyzed hydrolysis of a 
phosphinamide such as 66a proceeded at 105 more rapidly than the corresponding 
carboxylic amide 67.10 
24 
In a study on the use of a phosphorus protecting group in the form of a phosphor-
amide, the diphosphinyl protecting group was removed almost quantitatively by treatment 
with gaseous hydrogen chloride in THF at room temperature to give the corresponding salt 
68.78 Moreover, the cleavage of a bis(phenoxyphosphinyl) group was achieved via mild 
+ -




hydrogenation (30 psi) in the presence of platinum oxide to give the corresponding 
deprotected amine 69.86 
Spectral identification is critical in all synthetic work and especially for phosphorus 
compounds. In general, the presence of a P=O group is recognizable by infrared (IR) 
analysis 77 via the presence of a medium to strong absorption band between the limits of 
1087 and 1415 cm-1.77 Likewise, P-N groups show one or two absorption bands with a 
frequency range of789-1102 cm-1, and no consistent absorption band has been detected at 
lower frequencies.77 Three absorption bands are found in the spectra of all compounds 
containing a P-aryl group.77 The bands are of weak to medium intensity and occur within 
the frequency ranges of 1420-1455 cm-1, 990-1010 cm-1, and 482-562 cm-1.77 
25 
Compounds containing P-0-Ph and P-N-Ph groups also have absorption bands with 
frequencies close to 1400 cm-1,77 The ranges for the two groups of compounds are: 
1445-1458 cm-1 (P-0-Ph) and 1379-1425 cm-1 (P-N-Ph). 
No direct correlation for the presence of a P=O group is available via 31p NMR 
analysis. 77 The 31 P chemical shifts, relative to 85% H3P04, for trivalent phosphorus 
compounds range from -228 to +256 ppm, whereas those for tetravalent compounds 
containing a P=O group range from -85 to +103 ppm.77 
CHAPTER II 
RESULTS AND DISCUSSION 
We have been able to effect the synthesis of the compounds shown in Figures 1-5. 
Amides 70-72 can be classified as phosphorylated aromatic amines ranging from a 
simple aniline system to heterocyclic aromatic systems. Phosphorylation was 
accomplished using Ph2P(O)Cl or (ArOhP(O)Cl under different reaction conditions (see 
Experimental). Regiospecific phosphorylation of adenine was also accomplished with 









(a) Ar =Ph; (b) Ar = OPh; (c) Ar = O-C6H4-4-CH3 
Figure 1. Structures of phosphorylated aromatic amines and heterocyclic amines. 








Figure 2. Structures of phosphorylated adenine derivatives. 
26 
27 
Compounds 76 and 77 with a two-carbon side chain to the parent adenine molecule 
were prepared as starting materials for compounds 78-81, and 82-84, respectively 








Figure 3. Structures of adenine derivatives with a two carbon side chain. 
phorylation of 76, whereas phosphoramide 80 and ester 81 were obtained via the 
unexpected simultaneous chlorination and phosphorylation of 76 with the corresponding 
phosphorus reagent. The phosphorylated and non-phosphorylated azido-alkyl derivatives 
82-84 were prepared from 77 via a different sequence of reactions to be discussed 
shortly. The concept of incorporating the azido group was based, in part, on the known 
28 
activity of the azido-substituted, clinically-approved drug AZT (19) as a model 
compound. 36,83 
A new strategy for producing potential antiviral agents was explored in which the 
chelation of Zn+2 was anticipated to participate in the operating mechanism which has been 
deemed responsible for activity.67 The heterocyclic derivatives of adenine 85-89 (Figure 
4) were obtained via condensation of 77 with the appropriate aminomethyl derivative of 
6' 
70(~5' 








6o:~ 86 R = I 4' 
7' .& 8' 
N 
3' 
87 R = 
7rr.s 4' 88 R = 
6'~ A5. 
7'~0'-¥ 
89 R = V,.. 
6' 5 
):::Phh 
~~-,l ~ 1' N N 
90 91 
0 5' 6' 
N 
Figure 4. Adenine heterocyclic derivatives as potential chelating agents. 
derivative of the heterocyclic system. Two different pyridine derivatives (86 and 87) of 
the above mentioned compounds were regiospecifically phosphorylated with two different 
29 
phosphorus agents to obtain 90 and 91. The described potential antiviral agents 76-91 
were synthesized by design in such a manner so as to allow individual preparations and 
thereby permit a comparison of the non-phosphorylated adenine derivatives with their 
phosphorylated counterparts in terms of their antiviral activity. In collaboration with Dr. 
Suhadolnik (Temple University), a current investigation of some of the compounds from 
our work is underway to determine the presence or absence of antiviral activity in several 
different lines of viruses. 
Another modification to the purine system of adenine was initiated by attempting to 
introduce a phosphorus atom or group in the imidazole moiety of the purine ring. Several 
synthetic methods were explored, but all primarily involved cyclization reactions to affect 
ring closure of a few diamino systems. However, the only product purified and identified 
was the unexpected dimer 92 (Figure 5) which may constitute a novel potential antiviral 





Figure 5. Structure of the novel dimer formed during an attempted cyclization reaction. 
30 
Synthetic Methodology 
Adenine (1) is an important nucleoside base found in DNA and RNA, and therefore 
this base provides a key site for potential modifications to alter the replication process in 
viruses. From Chapter I it was seen that slight modifications in the structure of nucleic 
acid derivatives can significantly change the observed antiviral activity of a 
system}3,15,18,33,54,65,66,74,79,83 Moreover, there are no exact requirements as yet for 


















+ Ar2P(O)Cl . 
96 94 72 
(a) Ar =Ph; (b) Ar = OPh; (c) Ar = O-C6H4-4-CH3 
31 
modifications on adenine or on an adenine derivative might conceivably produce a 
potential antiviral agent 
A literature search in the area of phosphoramides, in particular aromatic 
phosphoramides, indicated that there is an apparent lack of comprehensive data on the 
NMR properties of such compounds. Since most of the anticipated products of this 
project were expected to be phosphoramides, it was essential to prepare a number of 
simple phosphoramides as models to evaluate their NMR spectral data. 
The aromatic phosphoramides 70-72 were synthesized according to Scheme I. The 
aniline derivatives 70a, 70b, and 70c were obtained as reported in the literature69 as 
colorless, crystalline solids (anhydrous C2HsOH), mp 238.5-239.5oC (lit69 239-240°C), 
130-131 oc (lit89 129-130°C), and 130-131 oc (lit2 125°C), respectively. The 
phosphorylated pyridine derivatives 71a, 71b, and 7lc (Figure 1) were also 
synthesized as reported31 and obtained as white crystalline solids (anhydrous C2HsOH, or 
HCC13fether), mp 172.5-173.5oC (1it31173-174°C), 197.5-199°C (lit24 190-191 OC), 226-
227oC (lit24 215-216oC), respectively. 4-Aminoquinaldine (96) was phosphorylated 
under similar conditions (Et3N/toluene) to give compounds 72a and 72b in modest yields 
(15%, 20%, respectively) and as white crystalline solids (benzene) with mp 159-1600C, 
and 180-181 oc, respectively. 
The following spectral patterns were observed for compounds 70-72: (1) IR: N-H 
bands vary in intensities; 70a, 3120; 70b, 3195; 70c, 3190; 71a, 3200; 7lb, 3140; 
71c, 3110; 72a, 3260; 72b, 3260 cm-1. The P=O bands were generally of medium 
intensity and (Table VIII) appeared at 1220-1240 cm-1• This is in accordance with the 
P=O bands found in the literature.76 (2) Mass spectra: None of the phosphorus 
compounds prepared to date show molecular ions using the EI technique (70 e V), and Dr. 
Geno did not recommend the use of (30 eV). However, with the FAB technique the 
molecular ions were observed in the form of [M+·+ 1]. The reason for the success of 
the F AB technique is that ionization occurs from the solid at room temperature and sample 
TABLEVIll 
31p NMR AND IR SPECTRAL DATA OF 70-72 





(a) Ar =Ph; (b) Ar = OPh; (c) Ar = O-C6H4-4-CH3 
Compd 70a 70b 70c 71a 71b 71c 72a 
31Pppma 17.4 -6.2 -5.8 19.7 -7.9 -41.1 -0.6 
N-H cm-lb 3120 3195 3190 3200 3140 3110 3260 
P=Ocm-lb 1240 1235 1240 1227 1220 1225 1225 
aJn DCC13 using an external reference (85% H3P04). 






volatilization is not necessary. Hence, thermal effects are avoided.4 (3) lH NMR: The 
presence of the phosphorus atom appeared to shift all proton signals and created a high 
signal density which did not allow accurate assignments of the proton peaks. The N-H 
proton signals were visible in the spectra of all the derivatives in the form of a broad 
doublet with coupling constants ranging from 5.2-17.1 Hz. The chemical shifts of theN-
H proton are greatly solvent dependent. In DMSO-d6, the proton on N appeared around 
8.3 ppm for 70a and around 6.9 ppm for 70b (DCCl3). (4) 13C NMR: All expected 
carbon signals were present in the 13c spectra (Table IX). Due to the presence of an aryl-











13C NMR SPECTRAL DATA OF 70-72a (PPM) 
iJ~(O)M2 
" 70 





(a) Ar =Ph; (b) Ar = OPh; (c) Ar = O-C6H4-4-CH3 
C(1) C(2) C(3) C(4) Ar-C 
141.9 131.5 128.4 120.4 118.1, 128.6 
131.7, 132.3 
138.9 129.7 129.3 118.1 120.3, 122.3 
125.3, 150.2 
139.0 130.1 129.3 118.1 120.1, 122.2 
134.8, 148.1 
149.8 130.1 148.8 113.1, 128.8 
131.7, 132.5 
149.7 129.9 149.6 112.4, 119.9 
125.4, 150.2 
150.3 134.0 147.5 112.3, 119.6 
130.2 










asamples were run in DMSO-d(j referenced to TMS (tetramethylsilane) at 0 ppm. 
33 
experience close chemical shifts. Coupling of P to C was also observed. (5) 31p NMR: 
One signal appeared for each compound. The chemical shift, relative to the standard, 
34 
depended upon the presence of two oxygen atoms adjacent to the phosphorus atom and 
which induced a negative 3lp chemical shift such as for 70b, 70c, 71b, 71c, 72b, and 
72c (fable VIII). The absence of these oxygen atoms resulted in a positive 31p chemical 
shift (fable VIII) from the standard (85% H3P04) such as for 70a, and 71a . 
To the best of our knowledge, the amino group at the 6-position in adenine has not 
been phosphorylated to date. Therefore, phosphorylating adenine was of interest in terms 
of the physical properties of the product as a prodrug in addition to the potential role of 
such compounds as antiviral agents. The phosphorylation of adenine 1 (Scheme II) was 
SCHEME IT 
NHZ 
_C_l-_Z_(_94_) _ ____,~ ,f~N¥H + 
pyridine H~N~N 
94a Z = P(O)Ph2 




73 Z = P(O)Ph2 
74 Z = P(O)OPh2 
0 r+ cr 
97 H 







achieved by a condensation of the 6-amino group of adenine in pyridine with three 
different phosphorus agents all of which had a P(O)Cl functional group. An intermediate 
trigonal bipyramid (TBP) was anticipated, followed by an elimination of HCl which was 
35 
scavenged by pyridine, to afford the phosphoramide derivatives 73 (mp 231-233·c, 
16%), 74 (mp 118.5-12o.o·c, 12.2%), and 75 (mp 205-206.5·c, 48%). An attempt to 
increase the yield of 73 by increasing the reaction time to 6 h resulted in a 10% reduction 
in the yield of 73. Pyridine hydrochloride (97) was the major by-product. Note that 94c 
refers to a previous derivative on page 30. 
Purification of 73 was not successful by the following techniques: recrystallization 
(H20, C2HsOH), column chromatography (silica gel, neutral alumina), sublimation, and 
HPLC (H3COH:H20; 70:30). It was suspected that diphenylphosphinic acid 
[Ph2P(O)OH, 98] was the impurity present in the desired product 73. This is based on 
the observation that separation of acid 98 occurred during workup. Moreover, one 
fraction CTR =12.45 min) of crude amide 73 obtained from the HPLC column (C-18, 
reversed phase) contained a solid (mp 193-195. C; IR (KBr), 3070, 1700, 1200, cm-1), 
which was identical to a sample of acid 98 prepared independently by the hydrolysis of 
diphenyl phosphorochloridate. 
Compounds 7 4 and 7 5 were obtained in pure form by means of column 
chromatography (silica gel) and were further purified by recrystallization [7 4 
(HCCl3:ether; 2:20); 75 (HCCl3:H3COH:hexane; 10:1:7)] via the diffusion method. 
Another workup procedure involved washing a chloroform solution of the crude product 
with H20, followed by evaporation of the solvent and then trituration of the liquid to give 
a white solid. Recrystallization from the above mentioned solvents gave analytical 
samples. 
The 1H, 13C, and 31p NMR spectra of 73 (crude), 74, and 75 support the proposed 
structures although the signal density is high in both proton and carbon patterns. The 1 H 
NMR analysis for 73 clearly shows the two proton signals H(2) and H(8) at 0 8.18 and 
8.35, respectively (Table X). However, the 1 H NMR signals of H(2) and H(8) for 7 4 
and 75 appeared to be in the form of one broad signal at 0 8.37 and 8.40, respectively, 
perhaps due to a shielding effect from the two phenyl groups attached to phosphorus. 
TABLE X 






73 Z = P(O)Ph2 
74 Z = P(O)(OPhh 









asamples were run in DMSO-li{; referenced to TMS (tetramethylsilane) at 0 ppm. 
bShifts in ppm from 85% H3P04. 
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A more severe effect was observed in the 13C NMR spectra of 73-75 where the carbon 
atoms of the adenine ring were all under a complex, broad signal envelop at 142.4-150.6 
ppm. The carbon atoms of the phenyl and of the aryloxy groups [C(1'), C(2'), C(3'), 
C(4'), C(5'), and C(6')] appeared as expected within a range of 120.2-134.6 ppm. The 
31p NMR analysis (Table X) of crude 73 showed a positive chemical shift at 18.3 ppm, 
but for 7 4 and 7 5 a negative chemical shift was observed at -7.9 and -8.3 ppm, 










The UV spectrum of 74 was recorded [Amax 268 (sh, 263, 283), MeOH], and the data 
were compared to that of N6-diphenylphosphoryl-2-deoxyadenosine [100, Amax 260 (sh, 
285, 268) Me0H]24 as shown in Figure 6. The close correlation of the absorption bands 
was considered as confirmation that the phosphorus moiety alters only slightly the 
conjugation in the system, with the basic electronic framework intact. 
NHP(O)(OPh)z 
N~N" 
l~T;L 7 N N 
Ho~oj [mp 144-14s·c] 
\-/_too 
OH OH 
UV: Amax 260 (285, 268) [MeOH] 
logE: 4.27 (4.13, 3.40) 
NHP(O)(OPh)2 
N~\_ 
lH;l 7 N N 
I 
H [mp 118.5-120·c] 
74 
UV : Amax 268 (263, 283), 208 [MeOH] 
log E: 3.99 (3.99, 3.89), 4.3 
Figure 6. The UV data of a phosphrylated adenine derivative and of a model 
phosphorylated adenosine. 
It has been shown that a new class of purine derivatives exhibit potent antiviral 
activity42 such as was observed with (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-
purines [with adenine the compound is designated HPMPA (101) ; with guanine the 
compound is designated HPMPG (102)] as illustrated. Viruses affected include herpes, 
(101) X = OH , Y = NH2 
38 
adeno, irvido, MSU, and HIV.42 It was suggested that the two carbons between the 
purine base and the phosphonomethoxy functionality were important for optimal 
antiviral activity.42 It was also postulated that (S)-HPMPA (34) and (R,S)-HPMPG 
(102) are taken up by cells and phosphorylated intracellularly to the corresponding 
diphosphoryl derivatives which are selective viral DNA polymerase inhibitors.42 
The above observations prompted the idea of synthesizing phosphorylated adenine 
derivatives with a two carbon side chain which possessed a good leaving group at the 2'-
position. This type of drug design might allow two possible mechanisms to operate 
(Figure 7): (1) hydrolysis at the alkoxy group to produce the hydroxyl derivative in vivo, 
or (2) hydrolysis at a good leaving group such as X producing the phosphorus acid 
derivative in vivo. In both cases, the phosphorylated adenine derivatives could function as 
prodrugs. The initial intent was to phosphorylate the hydroxyl group of the alkyl chain in 
the adenine derivative 76. Scheme III illustrates these reactions for the preparation of 
'/ N 2' 
1'~ ?! 
~~ru 
X= OAr, Cl 
Ar=Ph, OPh 
Figure 7. Two anticipated operating hydrolysis processes. 
compounds 78, 79, and 80. Pyridine was used as the solvent and for scavenging the 
HCl formed during the reaction. Purification of compounds 78-80 was accomplished via 
column chromatography using silica gel with a solvent mixture (CH30H:HCCl3; 10: 1). 
Compounds 79 and 80 were also further purified by flash chromatography using a 
solvent mixture (CH30H:HCCl3; 30:1). Pure 78 (mp 199-200°C, 42%) was obtained as 
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79 Z = P(O)(OPhh 
(41%) 
Z = P(O)(O-C6H4-4-CH3h 
(16%) 
crystalline solid (C2HsOH:ether) by the diffusion method. Note that compounds 79 (mp 
175-176.5°C, 41%) and80 (mp 152.5-154°C, 16%) resulted from phosphorylation of 
the N6-amino group in 76 as well as chlorination of the 2'-position. These compounds 
may be hygroscopic on long exposure to air, but this was not checked. Compound 77 
was obtained as a side product in the formation of 79, but, as a structure proof, 77 was 
converted to 79 by an independent route (Scheme IV) using the same phosphorus reagent 
ClP(O)(OPh)2 as well as workup and purification procedures. Both products were 
identical in terms of their physical and spectral data.It is conceivable that in the conversion 
of 76 to 79 or 80 an initial phosphorylation occurs at oxygen. This intermediate could be 








phosphate or phosphonate group as shown in Figure 8. The new 
intermediate, such as 77, could then be phosphorylated at N(6) to give 79 or 80. This 
hypothesis has some credence since we could obtain 79 from 77. 
0 
~-/! 
R ( pj 'x 
Cl 
X= Cl, OPh 
Ar=Ph, OPh 
Figure 8. Possible mechanism for the generation of 77. 
The IR spectrum of 78 indicated the presence of an amino group in the form of two 
distinct absorption bands at 3300 and 3120 cm-1. In the lH NMR analysis of 78 (Table 
XI), it appeared that, in contrast to spectra for the phosphorylated derivatives 73-75, 
signals for H(2) and H(8) were clear at the expected chemical shifts (B 8.1, 8.2, 
respectively). Moreover, the Be spectrum of 78 showed all the peaks (Table XII) for the 
carbons in the adenine group, a situation not observed in the spectra of73-75. 
For compounds 79 and 80 (Table XI), signals for H(2) and H(8) do not appear as 
clearly defined as in 78. In fact, the chemical shifts (B 8.05; 8.02 in 79 and 80, 
respectively) are displayed in a manner that defies explanation at this time. However, the 
13C NMR spectra show clear peaks for the adenine carbons for both 79 and 80 (Table 
XII). Surprisingly, the intensity of carbon signals of adenine in both 79 and 80 were 
TABLE XI 
lH NMR AND 3lp NMR SPECTRAL DATA FOR 78-80 







H OP(O)Ph2 8.11 8.21 4.2 
79b P(O)(OPh)2 Cl 











asamples were run in DMS0-£16 referenced to TMS (tetramethylsilane) at 0 ppm. 
bSamples were run in DCCl3 referenced to TMS (tetramethylsilane) at 0 ppm. 
CA1l31p shifts in ppm from 85% H3P04 as an external standard. 
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spectra of the four phosphoramide derivatives of adenine, namely 73, 74, 75 and 78, it 
is tentatively concluded that the effect of the phenyl groups on the phosphorus moiety may 
influence the NOE magnitude of the carbon atoms in the adenine ring as well as change the 
chemical shifts thereof. Of course, coupling of P with C increases the complexity of the 
C-13 spectra. The 31p NMR (Table XI) signals for 78-80 followed the pattern observed 
for the previously prepared compounds (70-75, Table VIII and X) where a positive 
chemical shift was observed for the phenyl derivative 78 (31.67 ppm) and a negative 
chemical shift was observed for the aryloxy derivatives 79 and 80 (-8.91 ppm and -8.97 
ppm, respectively). 
From the above observations, it became of interest to design a derivative which 
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TABLE XU 
Be NMR SPECTRAL DATA FOR 78-80 (PPM) 
78 Z = H, Y = OP(O)Ph2 
- 79 Z = P(O)(OPhh , Y = Cl 
80 Z = P(O)(O-C6H4-4-CH3h , Y = Cl 
Compd C(2) C(4) C(5) C(6) C(8) C(l') C(2') 
78a 152.3 149.5 118.7 155.9 141.0 40.2 43.4 
79b 151.1 150.2 120.7 152.2 144.1 45.8 42.0 
sob 151.2 150.9 119.9 152.0 143.8 45.8 42.0 
asamples were run in DMSO-% referenced to TMS (tetramethylsilane) at 0 ppm. 
bSamples were run in DCCl3 referenced to TMS (tetramethylsilane) at 0 ppm. 
possessed a phosphorylated side chain containing a good leaving group such as a chloride 
ion or a phenoxide ion. Potential phosphorus reagents for such a purpose are 
phenylphosphonic dichloride (103), phenyl dichlorophosphate (104) and phenyl 
phenylphosphono chloridate (105). The latter compound (105) is not commercially 
available and therefore, was prepared according to a literature procedure.49 Pure 105 was 
obtained after a double fractional distillation [bp 166-170°C/2.5 mm Hg (lit49 92-98°C/0.3 
mm Hg)]. Upon treatment of the above mentioned phosphorus reagents with 9-N-
hydroxyethyladenine (76, Scheme V), only the reaction with phenyl phenylphosphonic 
chloridate (105) proceeded to the desired product 81 (50%). The latter compound was 
purified by column chromatography (silica-gel) using a solvent mixture of (HCCl3:ether; 
10:1). Pure 81 was obtained as an amorphous powder (HCCl3:ether), mp 145.5-146°C 
SCHEMEV 
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(50%). The reactions involving phenylphosphonic dichloride (103) and phenyl 
dichlorophosphate (104) unexpectedly gave the chloroethyl derivative 77 of adenine in 
yields of 29% and 38%, respectively, along with some tar-like material that could not be 
purified or crystallized by chromatography or trituration. The formation of 77 might be 
explained in terms of proceeding through a phosphorylated intermediate as was shown in 
Figure 8. 
An interesting feature in the lH and 13C NMR spectra of 81 was that the lH NMR 
signals for both H(l ') and H(2') overlapped (o 4.53) under one broad envelop, but the 
13C signals for C(l ') and C(2') occurred as two distinct patterns ( 44.05 and 64.31 ppm, 
respectively), a situation not observed in any of the previously prepared phosphorylated 
adenine derivatives. Thus, a HETCOR experiment was performed on 81 to characterize 
and assign the signals to the proper protons. It was apparent that the two signals for these 
protons do in fact overlap in the HETCOR plot (Figure 9) which raises the question of the 














68 66 84 62 80 !58 !56 54 52 ~0 48 46 44 42 
F2 IPPMI 
0::: --
Figure 9. HETCOR plot of 81 correlating H(l') and H(2') to C(l') and C(2'). 
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ester 81 is that the 31p NMR signal appeared at 15.32 ppm which could not have been 
predicted considering the presence of both a phenyl group (giving rise to positive 31 P 
chemical shifts) and a phenoxy group (giving rise to negative 31p chemical shifts) on the 
phosphorus atom as observed for 70-75 and 78-80 and cited previously. 
Another idea which related the molecular structure of the molecules of interest to the 
structure of AZf (19) was also investigated. 36 The presence of the azido group in AZT is 
the only difference from that of the naturally occurring nucleoside thymidine (106),64 and 
it has been proposed that the charge distribution on the azido group may mimic the charge 
distribution on the phosphate group as stated earlier. Thus these groups may be 
accommodated at the nucleotide binding site present in the transcriptase.4 Therefore, it 
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HOH2C 
19 (AZT) OH 106 (Thymidine) 
was decided to synthesize a group of adenine derivatives containing an azido group in 
addition to placing phosphorus groups at strategic positions in the system. Consequently, 
the proposed derivatives might exhibit prodrug characteristics. Compounds 77-80 were 
treated with sodium azide in DMSO at 80 • C, with boiling benzene as the heating source 
(Scheme VI). The reaction proceeded smoothly, but the yields of organic azides 82-84 
were modest ranging from 36-39% yield. The lH and 13C NMR spectra of 82-84 
varied only slightly from those of 77-80, except for the upfield shift of H(2') and 
C(2') in the former (see data in Table XIIT for comparison). 
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lH NMR,13C NMR, AND 3lp NMR SPECfRAL DATA FOR 
77,79,SO, ~D S2-S4 
77 Z=H, Y=Cl 
6NHZ 7 79 Z = P(0)(0Ph)2 , Y = C1 IN:J:N> I 's so Z = P(0)(0-C6lf4-4-CH3h , Y = C1 2~ 
N 4 N 9 2' 82 Z=H, Y=N3 3 I\-\ 
y 83 Z = P(0)(0Ph)2 , Y = N3 
84 Z = P(O)(O-C6H4-4-CH3)2 , Y = N3 
0H(2) 0H(8) 0H(1) 0H(21 31pc 
8.17 8.19 4.50 4.08 
8.05 (broad) 4.5 3.9 -8.91 
8.02 (broad) 4.5 3.9 -8.97 
8.17 (broad) 4.35 3.80 
8.03 (broad) 4.32 3.77 -9.27 
8.00 (broad) 4.30 3.78 -9.23 
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Compd C(2) C(4) C(5) C(6) C(8) C(l') C(2') 
77a 152.4 149.4 118.6 155.9 140.9 44.7 42.7 
79b 151.1 150.2 120.7 152.2 144.1 45.8 42.0 
SOb 151.2 150.9 119.9 152.0 143.8 45.8 42.0 
s2a 152.4 149.5 118.6 155.03 140.7 49.6 42.4 
SJb 151.1 150.9 120.7 152.2 143.8 50.0 43.2 
S4b 151.2 148.1 120.4 152.2 143.7 50.1 43.2 
asamples were run in DMSO-li6 referenced to TMS (tetramethylsilane) at 0 ppm. 
bSamples were run in DCCl3 referenced to TMS (tetramethylsilane) at 0 ppm. 
CA113lp shifts in ppm from 85% H3P04 as an external standard. 
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To date, no information is available on the chloro compounds 77, 79, and 80 
compared to the corresponding azido derivatives 82-84 in terms of biological activity. It 
was noteworthy that phosphorylation of the azido derivative 82 with the 
chlorophosphorus reagents 94b and 94c using pyridine as the solvent (or Et3N/toluene 
conditions) was unsuccessful. Only tar-like material that could not be separated by 
chromatography or induced to crystallize by trituration was obtained. 
CIP(O)(O-C~-4-CH3h (94c) 
CIP(O)(OPhh (94b) 
83 Z = P(O)(OPhh 
84 Z = P(O)(O-C6H4-4-CH3)z 
Another working hypothesis was considered in the preparation of adenine acyclic 
derivatives which might display antiviral activity. Heinrikson and co-workers34 reported 
that zn2+ ions play a major role in the immune system and that immunodeficiency in 
cancer and AIDS patients is often accompanied by Zn2+ deficiency. It was also sugessted 
by the same author that a ligand could be designed for tight binding both to Zn2+ and to 
the enzyme target, thereby producing a specific inhibitor for therapeutic evaluation. In a 
separate study on catalytic transesterification and hydrolysis of RNA by zn2+ 
complexes, 67 it was shown that three macrocyclic amine ligands (Figure 10) bound 
efficiently to zn2+ to form complexes 107-109 which maintain zn2+ in solution at 
neutral to mildly alkaline pH. In general, studies on the chelation potential of ions present 
in the immune system is very limited which makes this concept rather novel. 
From the above studies on zn2+ it was decided to prepare several potential chelating 











107 108 109 
Figure 10. Structures of three amine-zinc complexes. 
anticipated molecules should contain sets of 3 or 4 nitrogen atoms in the adenine derivative 
oriented as shown in Figure 11 and in such a manner that mimics the above mentioned 
amines which have the potential to chelate a zinc atom with 3 or 4 N atoms. 
++ 
Figure 11. Structure of a proposed adenine metal complex. 
Five different aminomethylpyridine reagents, namely 2-(aminomethyl)pyridine (110), 
3-(aminomethyl)pyridine (111), 4-(aminomethyl)pyridine (112), 2-thiopheneamine 
(113) and 2-furfurylamine (114) were employed to generate potential chelators 85-89. 
The reaction of 77 with the appropriate amino compounds proceeded as shown in Scheme 
VII. The yields of products were modest for the pyridine derivatives 85-87 (31 %-46%) 
and poor for the thiophene derivative 88 (20%) and furfuryl derivative 89 (19%). It is 
apparently common for such reactions to proceed in relatively low yields12 due to other 
competing reactions such as the dialkylation of the amino group or perhaps the self dimer-
SCHEMEVll 
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In the purification of 85-89 TLC analysis showed poor separation of compounds in 
the reaction mixtures using 4 different solvent systems such as HCCl3:CzHsOH, 
EtOAc:CzHsOH, EtOAc:H3COH, and benzene: CH30H. However, using a mixture of 
HCCl3:H3COH (10:1, or 15:1) did achieve some separation. Purification by means of 
column chromatography (silica gel) was unsuccessful, since a fraction with a very close Rr 
value to that of the desired product could not be separated. The Chromatotron was then 
used to achieve a good separation affording pure materials all of which were recrystallized 
from HCC13 to give crystalline solids with sharp melting points [85, (163-164°C); 86, 
(166-16TC); 87, (161.5-162.5°C); 88, (192-193°C); 89, (182.5-183.YC)]. 
It was decided to undertake different synthetic approaches to improve the yields of 
compounds 85-89. The first method used Et3N/toluene in the reaction of 2-
aminomethylpyridine with the chloride derivative 77. The reaction mixture was heated 
under reflux for 4 h. After cooling, filtering off the white precipitate, and concentrating 
the filtrate, a yellow syrup was obtained which was applied to a Chromatotron plate and 
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eluted with a solvent mixture (HCC13:H3COH; 10:1). Two bands were isolated, one of 
which was identified as the starting material by IR and lH NMR analysis, and the other 
band was identified as the desired product 85 by comparison of the IR, 1 H NMR and 13C 
NMR spectra to that of a previously prepared sample. However, the yield of 85 from this · 
reaction was 10%, which was less than the yield previously obtained by using 
pyridine as the reaction media. 
The second approach was using Et3N/n-butanol for the condensation of 2-
aminomethylpyridine with the chloride derivative 17. Progress of the reaction was 
followed by TLC (HCCl3:H3COH; 10:1) analysis which indicated the disappearance of 
the starting material after 20 h. Cooling the reaction mixture and evaporating the solvent 
gave a semi-solid which was applied to a Chromatotron plate and eluted with a solvent 
mixture (HCCl3:H3COH; 10:1). Collection of the second band and evaporation of the 
solvent gave a solid which was recrystallized (HCCl3) to give solid 85 (54%). The same 
reaction conditions were employed for the reaction of 3-methylaminopyridine, 4-
methylaminopyridine, 2-thiophenemethylamine, and 2-methylfurfurylamine to give the 
desired products 86-89 in yields of 56%, 50%, 44%, and 45.5%, respectively. Thus, 
the reaction conditions using Et3N/n-butanol were the most effective in terms of improving 
the yields of 85-89. 
Following the previously proposed hypothesis that the adenine N-phosphorylated 
and a-phosphorylated phosphorus derivatives may act as prodrugs for the inhibition of the 
HN virus replication process, it was decided to phosphorylate two of the adenine aromatic 
cyclic derivatives 86 and 87. Two approaches were used (Scheme VITI). First, pyridine 
was used as the media for the reac~ion of phosphorus derivative 79 with 3-
aminomethylpyridine (111) to give 90. The residue obtained from evaporating the 
solvent was separated on two successive and nearly identical Chromatotron plates. 
However, two different solvent mixtures had to be employed for elution (HCC}J:H3COH; 
15:1, and 25:1). Collection of the second band and evaporation of the solvent gave a 
SCHEME VIII 
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colorless oil which, upon drying under reduced pressure, gave a foamy solid which was 
crystallized (HCCl3:ether; 3:25) by the diffusion method to give a white crystalline solid of 
90 (mp 59.4-60.5°C) in a low yield (11% ). This product appeared to be hygroscopic and 
required the vigorous exclusion of air and moisture in the final work-up of the compound. 
Similarily the adenine derivative 80 was treated with 4-aminomethylpyridine (112) 
using identical conditions for the reaction, workup, and purification (as in the preparation 
of 90) to give compound 91 (Scheme Vlll). Pure 91 was obtained (14%) as a white 
crystalline solid (HCCl3:ether; 5:20) by the diffusion method (mp 71-72°C). It was noted 
that the latter compound was also very hygroscopic and required special handling. 
The second approach involved the condensation of adenine derivative 80 with 4-
methylaminopyridine (112). This was attempted using conditions (Et3N/n-butanol) 
previously cited in the reaction of the adenine derivative 77 with 2-methylaminopyridine 
(110). However, upon workup of the reaction mixture, starting material was isolated in 
addition to some intractable materials. 
Another method involved phosphorylation of 85 with diphenyl chlorophosphate 
(94b) in pyridine. A major color change was observed (yellow to dark brown). 
Attempted separation of the mixture on a Chromatotron plate produced starting material in 
addition to some intractable substances. Keeping the reaction temperature at room 
temperature gave the same results. 
The 1 H NMR spectra of 90 and 91 exhibited outstanding first order patterns giving 
rise to signals corresponding to all the protons present in the systems with the exception of 
H(2) and H(8) (Table XIV) which appeared as one broad envelop for both 90 and 91. 
Protons H(l'), H(2'), and H(3') appeared at the expected chemical shifts. 13C NMR 
spectra (Table XIV) of 90 and 91 also gave rise to all expected signals including those 
from the adenine moiety. However, due to the high degree of overlap between the signals 
of the pyridine group, the aryloxy group, and the adenine group, it was not possible to 
accurately assign all the signals to specific carbon atoms. Nevertheless, specific signals 
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TABLE XIV 
lH NMR AND 13C NMR SPECTRAL DATA OF 90 AND 91a 
90 91 
Compd 
90 7.99 (broad) 4.26 3.04 3.76 
91 8.04 (broad) 4.32 3.07 3.79 
Compd C(2) C(8) C(1') C(2') C(3') 
90 151.06 144.16 47.81 44.15 50.58 
91 151.17 142.98 47.30 43.39 51.29 
asamples were run in DCCl3 referenced to TMS (tetramethylsilane) at 0 ppm. 
for C(1 '), C(2'), C(3'), C(2), and C(8) were assignable (Table XIV) based upon 
comparison of signals for similar carbons in amides 79 and 80. 
The IR spectra for 85, 86, 87, 90, and 91, are almost identical, but this is not 
surprising since the groups of the major absorbing bands (P=O and N-H, see 
Experimental) are similarly bonded. The 31p for 90 and 91 are reasonable signals for the 
phosphorus atoms and appear at ( -8.77 ppm and -9.23 ppm, respectively). 
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The second part of this project was to introduce a phosphorus group or atom into the 
basic skeleton of adenine. The literature data on this subject is discussed in Chapter I. 
Because a P atom in an adenine structure might not alter the system extensively and 
because theoretical calculations (Dr. Welch, University of Missouri at St. Louis) indicated 
that a P-containing adenine system with phosphorus at the 8-position was energetically 
feasible, we initiated a synthesis of such a structure. 3,4,5-Triaminopyrimidine (115) is 
commercially available only in the form of the hydrosulfate ·salt (116); therefore, our first 
attempt utilized 3,4,5-triaminopyrimidine hydrosulfate (116) as the starting material. 
Treatment of 116 with triphenyl phosphite (Scheme IX) employed a procedure similar to 
that utilized for the reaction of 4,5-diaminopyrimidine (117) with triphenyl phosphite.41 
The latter reaction was claimed to give the purine analog 118 shown below on the basis of 
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mp (360°C), mass spectral analysis (M+. 138+·), IR analysis (1210 and 775 cm-1) and 
elemental analysis. It was also demonstrated that the adenine analog 118 was moderately 
active against leukemia L1210.41 The crude, viscous product of the reaction of 116 with 









to give a pale yellow solid. All attempts to recrystallize or purify the isolated solid failed 
(including sublimation and chromatography). The 31p NMR analysis of the crude solid 
revealed a large number of signals, indicating a severe mixture had formed. 
As a second approach the triaminopyrimidine salt 116 was neutralized with NaOH 
(10%), and the crude amine was purified by sublimation to obtain pure 4,5,6-tri-
aminopyridine (115) (mp 252-254oC; lit70 mp 255-257°C). Pyrimidine 115 was treated 
with triphenyl phosphite in an identical fashion to that employed for the reaction of the 
triaminopyrimidine salt. However, a tar-like material was obtained after 2 h of heating. 
The third method involved the treatment of the triaminopyrimidine 115 with 
phosphorus trichloride as a different and possibly more reactive cyclization reagent. 
However, only a brown solid was obtained that could not be purified by the techniques 
described above. The above three reactions were repeated applying different reaction 
conditions including variations of the following parameters: reaction temperatures, 
reaction times, and the ratio of molar equivalents of the phosphorus reagents to the 
triaminopyrimidine. Nevertheless, all of the above efforts generated complex reaction 
mixtures that defied all attempts at separation. 
At this stage of the research it was decided to alter the approach, but keep the major 
goal unchanged, namely to introduce phosphorus into a system posessessing a backbone 
of a nucleoside. A possible synthon for this purpose was the diaminopyrimidine system 
119 (reported by Vince and co-workers81) which had two amino groups oriented in such 
a manner that would conceivably allow a cyclization reaction to take place. Another reason 
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for choosing this particular system was the fact that diamino compound 119 was the 
precursor of nucleoside 120 (Figure 12) which was reported to be a potent and selective 




Figure 12. Structure of the selected diamino system (119) and the model 
antiviral agent (120). 
The diaminopyrimidine 119 was synthesized according to Scheme X as reported.19,81 
It is noteworthy to mention that the isolation of the diaminopyrimidine 119 was 
accomplished by simply passing the last reaction mixture through a column and eluting 
with a solvent mixture of (HCCl3:H3COH, 30:1).81 The recorded procedure indicated 
that it was essential to use a gradient elution system of (HCCl3:H3COH; 40:1, 30:1, 
20:1).81 Moreover, the residue obtained was treated with acetone to precipitate the 
triethylamine hydrochloride salt, but we found this step unnecessary for isolating the 
compound Our explan~tion for the precipitation step with acetone81 was that the reported 
elution technique with HCCl3:H3COH (30:1) had not permitted the complete separation of 
some of the triethylamine hydrochloride. The yields for intermediates in scheme X were 
about 10% lower than those reported in the literature exept for 125 which was obtained in 
an almost identical yield 
The last phase of the projected synthesis was to cyclize the diaminopyrimidine 119 
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reagent 104 was selected since the phenoxy group could conceivably be hydrolyzed in a 
later step as a preliminary approach towards the generation of a P=N functionality in the 
molecule via loss of PhOH and 0 to give the structure 127 which was one goal. Several 
experiments were performed in which a variety of conditions were employed utilizing 119 
with phenyl dichlorophosphate (104). First, heating the reagents in bromobenzene 
127 
at reflux for 3 h gave only tarry material and no useful product, as indicated by TLC 
analysis (HCCl3:H3COH; 10:1). This procedure was similar in nature to conditions 
previously cited for the reaction of a-phenylenediamine with phenyl dichloro-
phosphate.21 Second, pyridine was employed as solvent and several temperature (OOC, 
RT, 114°C) as well as several reaction times (2 h, 6 h, 24 h) were examined. However, 
TLC analysis (HCCl3:H3COH; 10:1) of all reaction mixtures did not indicate the 
generation of any expected material, although starting material was recovered. Third, 
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using Et3N/toluene20 and heating the reaction mixture at reflux for 4 h did not produce a 
new material. Starting material was recovered, and an -intractable substance was also 
obtained It appears that polymerization may be a serious competing process. 
It was decided that the solvent employed in this reaction must completely dissolve the 
starting material at room temperature since heating the reaction mixture previously always 
produced a dark brown mixture. Pyridine dissolved the starting material, but it appeared 
that there was a competing reaction that prevented formation of the product The solvent 
THF dissolved the starting material at room temperature, and it was unlikely that this 
solvent would undergo any reactions with the materials involved. Thus, THF was elected 
for the reaction of diaminopyrimidine 119 with phenyl dichlorophosphate. The reaction 
mixture was allowed to stir at room temperature for 24 h while being monitored by TLC 
(HCCl3:H3COH; 10:1) which indicated the slow formation of some new material. 
Purification of the oil-like substance required two runs through two identical 
Chromatotron plates but using a different solvent mixture for each (HCCl3:H3COH; 12:3, 
and 10:1, respectively). An oil was obtained (14.3%), which upon drying under reduced 
pressure, gave a foamy solid that would be recrystallized (HCCl3:ether; 5:20) to give a 
very light orange solid (mp 102-103.C). lH NMR, 13C NMR, and 31p NMR analyses, 
seem to indicate the presence of the desired product 126. However, mass specra (FAB) 
analysis of this product gave a parent molecular ion [M+·+ 1; 648+ 1]. The molecular ion 
(393) of the desired 126 was not observed. Considering different possible side 
reactions, it was found that a molecular mass [mlz = M+] of 648 might correspond to a 
product derived from the reaction of two equivalents of diaminopyrimidine 119 with one 
equivalent of phenyl dichlorophosphate, namely, 92 as shown in Scheme XI. All spectral 
data support the novel structure 92. Both 1 H NMR, and Be NMR show a high degree of 
symmetry which could easily be interpreted as supporting the desired product 126 as well 
as 92. Generation of phosphate 92 from this reaction suggests also that the nucleo-












amino (NH2) or the secondary amino (NH) group in this system or steric hindrance may 
occur at both amino groups and retard cyclization. The reaction of 119 with 104 was 
repeated using two equivalents of 104. However, no changes were observed in the 
product or in the yield of 92. 
It is interesting that the major differences in both the lH NMR and 13C NMR chemical 
shifts of the dimer 92, relative to that of the starting material 119, are only in H(4'), 
H(6'), C(4'), and C(6') (Table XV). This implies that formation of the dimer does not 
influence magnetic shielding at other positions of 92 and supports the suggestion that 
phosphorylation occurred at the OH group. 
Heating the reaction mixture of 92 and 119 reduced the effective reaction time from 
24 h to 6 h. In an attempt to promote the intramolecular reaction, the experiment was 
repeated under high dilution conditions using THF in large excess (8 times the original 
volume). However, formation of 92 as the only product occurred even after 6 days of 
TABLE XV 
lH NMR AND 13C NMR SIGNALS OF H(1'), H(2'), 
C(1'), AND C(2') OF 92 AND 119 
Compd ()H(4') ()H(6') C(4') ppm C(6') ppm 
92a 2.96 4.15 44.61 70.93 




stirring at room temperature. A literature search revealed that a few compounds similar to 
92 had been prepared.27 Farrow and co-workers27 proposed a new approach to the 
introduction of biologically active nucleosides into cells. Their method was based upon 
the observed phenomena that for nucleoside analogs to show biological activity, the action 
of kinase (cellular or viral kinases) to form the corresponding 5'-monophosphate was 
required The latter was then further metabolized before the active compound was formed. 
Therefore, the preparation of a phosphate prodrug could serve as an intermediate so that 
the monophosphate can be liberated inside the cell, thus avoiding the severe limitations 
invoked by kinases involved in the preliminary step. 
Farrow and co-workers27 prepared two compounds 128 and 129 and both showed 
antiviral activity in rabbit kidney cell cultures. It is also interesting that the yields of 128 
and 129 were low (19%, and 6%, respectively) as was the case in our preparation of 92 
(14.3%). Farrow explained the low yields in terms of the instability of both compounds 
(t112 = 17 h). The 3lp NMR signals of 128 and 129 were observed at -6.3 ppm and -6.6 
ppm, respectively, which compare well with the 31p shift of -6.5 ppm found for 92. The 
elemental analysis for 128 and 129 best fit if water was added namely, 
C22H24Br2N4012PNa·2H20 and C23H27NwOsPS·2H20, respectively.27 The analysis 










systems as 92, 128, and 129 have a marked propensity to attract water. 
Summary 
The main objective of this project was to prepare a variety of compounds which were 
potential antiviral agents, and more specifically anti-HIV agents, and consequently 
submiting the prepared compounds for the evaluation of their antiviral activity. The target 
compounds in this project could be divided into two groups based on the literature 
13,15,18,33,54,65,66,74,79,83 discussed in Chapter I. First, potential prodrugs, which 
include several phosphorylated adenine derivatives, were synthesized. These agents could 
be envisioned as useful prodrugs via hydrolysis of the phosphorylated compounds 
enzymatically in vivo and consequently releasing the potential antiviral agent in the cell. 
Second, several potential antiviral agents which interfere directly or indirectly with the 
replication of the DNA or RNA in the infected cell were also targeted for synthesis. These 
compounds included both the phosphorylated and certain non-phosphorylated adenine 
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reagents In the first part of this project we prepared 8 phosphorylated aromatic amines 
(70a, 70b, 70c, 71a, 71b, 71c, 72b, and 72c) and examined their lH NMR, 31C 
NMR, 3lp NMR, and mass spectroscopy spectra. A methodology was developed for the 
phosphorylation of adenine at the 6-position using three different aromatic phosphorus 
reagents to obtain the first phosphorylated adenine derivatives (73-75). 
A two-carbon side chain which contains an OH group at the 2'-position was attached 
to adenine at the 9-position, and the hydroxy product was then phosphorylated. Two 
types of phosphorylations were observed utilizing the same reaction conditions. The first 
phosphotylation occurred at the hydroxyl group giving a-phosphorylated products (78 
and 81), and the second occurred at the amino group giving .N6-phosphorylated products 
(79 and 80). 
Based on the structure of AZT (19) as a model compound for the design of potential 
antiviral agents, an azido group was introduced into three adenine derivatives (82-84) at 
the 2'-positon. Two of the azido compounds (83 and 84) were prepared from two 
previously obtained phosphorylated adenine derivatives. Five heterocyclic adenine 
derivatives (85-89) were synthesized and each contained a connecting side chain with an 
attached aromatic, heterocyclic ring. The products possess three N atoms and a 
heteroatom (N, 0, or S) in such orientations that should convey chelating properties for a 
zinc ion. The chelate may be a potential antiviral agent based on the suspected role of zinc 
in the immune system as discussed in Chapter I. We were able to obtain two 
phosphorylated-adenine derivatives (90 and 91) from 86 and 87. 
From the spectral analyses of the target compounds, the following general 
observations were made: (1) The lH NMR spectra of the products were not always of 
first order, in that broad signals were observed for selective protons H(2), and H(8). (2) 
The 13C NMR signals appeared in many cases as broad complex signals for the adenine 
carbons. The complexity of the lH NMR and 13C NMR signals was explained in terms of 
the effect of the presence of aromatic moieties in such a close proximity to the purine 
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system, and in terms of the P-C coupling effect. (3) 31 P NMR spectra showed one signal, 
and the chemical shifts depended on the presence (negative) or absence (positive) of two 
singly bonded oxygen atoms attached to the phosphorus atom. ( 4) For the mass 
spectroscopic analyses, it was found that only the FAB technique could be used to observe 
a molecular ion (EI failed even at lower energy levels). 
The second part of this project involved the introduction of a phosphorus atom into the 
imidazole moiety of the purine system. An unexpected product was obtained in the form 
of a dimer 92 from a cyclization reaction using a diaminopyrimidine 119. However, it 
was found that the product 92 is an analog of two reported dimers (128 and 129) which 
showed antiviral activity. A series of attempts was undertaken to introduce a phosphorus 
atom into the purine skeleton of adenine; however, all attempts gave complex mixtures. 
Compounds 73-80 are currently undergoing screening for activity against several 
viruses at Temple University (Department of Biochemistry), under Professor Robert 
Suhaldonik. 
Suggestions for Future Work 
There is an enormous demand for the development of new antiviral agents with a high 
level of selectivity. This is particularly true since only a few antiviral agents reach the 
clinical testing stage due primarily to increased toxicity commonly found at early stages. 
Even with the FDA approved drug (AZ1) for the treatment of HIV -infected patients, it has 
been found that there is a high degree of suppresion of bone marrow cell growth. 88 
The type of adenine derivatives prepared in our laboratories do not provide a 
comprehensive evaluation of the viral activity of such compounds, since there are 4 other 
nucleic acids present in the DNA or RNA. Therefore, it would be of interest to obtain 
similar derivatives by changing the base to make a different nucleic acid utilizing guanine, 
cytosine, uracil, or thymine. The importance of such a variation stems from the fact that 
many nucleoside analogs are only active as anitivral agents when one of the common bases 
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found in nucleosides is present and are completely inactive with any other bases. Thus, as 
shown below, compounds 130-133 could be important analogs of some of the 
compounds prepared in 
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our laboratories. The synthesis of these compounds should proceed in a similar manner to 
that used for the preparation of the adenine derivatives in this thesis. 
In the attempted cyclization of the diaminopyrimidine 119, we explained that the 
cyclization may not have occurred due to either steric hindrance or to the superior nucleo-
philicity of the OH group over the amino groups. To overcome both possible obstacles, 
the OH group could be protected with a stable protecting group such as a silyl (t-butyl 
dimethylsilyl, TBDMS), acetyl, or benzoyl which could be removed easily at a later stage. 
Moreover, the phosphorus reagent used could be an alkyl (such as methyl, ethyl, or 
isopropyl) phosphorus chloride, thus, minimizing steric hindrance. In addition, one of 
these methods could be used individually so as to generate 134 and 135, for example. 
Cl ~ 
NO 
N 'P-OR' I . 2 75 H2N J!. N W deprotection 2b, 
1 
~ I [H3COH. NH3 or 
RO 0 TIIF, CH,co,HJ 
134 
R = TBDMS, PhC(O), H3CC(O) 





General Information: Melting points were obtained on a Thomas-Hoover or an 
Electrothermal 9100 melting point apparatus and are uncorrected. IR specra were recorded 
on a Perkin-Elmer 681 as KBr pellets or neat films. All NMR spectra were taken on a 
Varian XL-400 BB spectrometer with 1H, 13C and 31P being observed at 299.94, 75.43 and 
121.48 MHz, respectively. Chemical shifts for 1H and 13C NMR specra were reported in B 
or ppm downfield from TMS [(CH3)4Si], while 31p NMR signals were reported in ppm 
downfield or upfield from 85 % H3P04 (0 ppm) as an external reference. Data are 
reported as follows: chemical shifts (in B values or ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet), coupling constants (in 
Hz), and assignments. Mass spectral data were recorded on a VG analytical instrument 
model, ZAB-2SE. Elemental analyses were performed by Galbraith Laboratories, 
Knoxville, TN 37921. 
Reactions were performed under an inert atmosphere of N2 with magnetic stirring. 
Reagent grade solvents were used without further purification and chromatographic 
separations were performed on silca gel (60-200 mesh, Aldrich), alumina (neutral, 70-230 
mesh, Merck) or silica gel (60, PF254, containing gypsum, EM Science). The following 
reagents were obtained commercially, and all liquid reagents were freshly distilled prior to 
use: 4,5,6-triaminopyrimidine sulfate (98%, Aldrich), triphenyl phosphite (bp 360°C, 
Eastman), phosphoryl chloride (bp 106°C, Eastman), 4-amino-5-imidazolecarboxamide 
hydrochloride (98%, Aldrich), adenine [98%, mp > 360°C(dec.), Aldrich], o-
phenylenediamine [Baker, recrystallized from 1% sodium hydrosulfite and dried (vacuum 
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pump, 24 h, 0.25 mm Hg, mp 101-103°C), dichlorophenylphosphine (bp 222°C, 
Aldrich), bromobenzene (bp 155-157°C, Fisher), phenylphosphonic dichloride (bp 258°C, 
Aldrich), o-dichlorobenzene (bp 180°C, Baker), benzyl bromide (98%, bp 198-199°C, 
Aldrich), N ,N-dimethylformamide (bp 74°C/35 mm Hg, EM Science), potassium 
carbonate (Fisher), phenyl phosphorodichloridate (bp 75-76°C/0.1 mm Hg, Aldrich), 18-
crown-6 (99.5%, Aldrich), sodium hydride (60% dispersion in mineral oil, Aldrich), 
pyridine (bp 114.5°C, Fisher), diphenylphosphinic chloride (bp 222°/16 mm Hg, 
Aldrich), ethylene carbonate (98%, Aldrich), thionyl chloride (bp 79oC), di(2-tolyl) 
chlorophosphate (bp 179-180°C, Aldrich), aniline (Aldrich), di(4-tolyl) chlorophosphate 
(bp 142°C/0.15 mm Hg, Aldrich), triethylamine (bp 89°C, Fisher), toluene (Fisher), 4-
aminopyridine (99%, Aldrich), 4-aminoquinaldine (TCI), sodium azide (99%, Aldrich), 
dimethylsulfoxide (Aldrich), 2-aminomethylpyridine (99%, bp 110°C/40 mm Hg, 
Aldrich), phenol (Mallinckrodt), dicyclopentadiene (Aldrich), p-toluenesulfonyl cyanide 
(95%, Aldrich), sodium borohydride (99%, Aldrich), calcium chloride (Baker), 2-
furfurylamine (99%, bp 143-145°C, Aldrich), 2-thiophenemethylamine (98%, bp 86-
870C/25 mm Hg, Aldrich), 3-aminomethylpyridine (bp 73-74 oC/1 mm Hg, Aldrich), 4-
aminomethylpyridine (98%, bp 230°C, Aldrich), 2-amino-4,6-dichloropyrimidine (99%, 
Aldrich), 4-chloroaniline (98%, Aldrich), sodium nitrite (Fisher), sodium acetate trihydrate 
(Mallinckrodt), and zinc (dust, 325 mesh, Aldrich). 
Bis(phenyl)phosphinanilide (70a). 69 To a boiling solution of diphenyl-
phosphinic chloride (94a, 1.61 g, 6.8 mmol) in benzene (5 mL) was added dropwise a 
solution of aniline (93, 1.27 g, 13.63 mmol) in benzene (5 mL) over a period of 15 min in 
a 2-necked, round-bottomed flask (50 mL) equipped with a condenser, and an addition 
funnel. A solid formed immediately and did not change in appearance during the heating 
and stirring process (1 h) at reflux. The mixture was cooled to room temperature (1 h) and 
then filtered. The precipitate was washed with warm water (4 x 5 mL) and dried in the 
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Abderhalden (80°C/5 mm Hg) for 5 h to yield 1.64 g (82%; lit69 80%) of crude product, 
which was recrystallized (anhydrous C2HsOH) to give colorless prisms of 70a (1.1 g, 
55%); mp 238.5-239.5oC (lit69 mp 239-240°C). IR (KBr) 3120 (N-H), 1445 (P-Ph), 
1240 (P=O) cm-1. lH NMR (DMSO-d6) () 6.8-7.8 (m, 15 H, Ar-H), 8.3 (d, NH, 2JP-H 
= 11.6 Hz); Be NMR (DMSO-d6) ppm 118.1 [d, C(4'), 4Jp_c =7Hz), 120.4 [s, e(4)], 
128.4 [s, e(3)], 128.6 [d, e(3'), 3Jp_c = 2.1 Hz], 131.5 [d, e(2), 3Jp_c = 9.8 Hz], 131.7 
[d, C(2'), 2Jp_c = 2.4 Hz], 132.3 [d, e(l'), lJp_c = 126.6 Hz], 141.9 [s, e(1)]; 31p 
(DMSO-d6; 85% H3P04, external reference) ppm 17.4. Mass spectrum (FAB) calculated 
for e1s Ht6NOP mlz [M+·]: 293; Found: [293+1]+7. The 1H NMR and Be NMR 
spectral data have not been previously reported. 
Bis(phenoxy)phosphinanilide (70b).69 To a boiling solution of diphenyl 
chlorophosphate (94b, 1.83 g, 6.8 mmol) in benzene (5 mL) was added dropwise a 
solution of aniline (93, 1.27 g, 13.63 mmol) in benzene (5 mL) over a period of 15 min in 
a 2-necked, round-bottomed flask (50 mL) equipped with a condenser and an addition 
funnel. A solid formed immediately and did not change during the heating and stirring 
process (1 h) at reflux. The mixture was cooled to room temperature (1 h) and then 
filtered. The precipitate was washed with warm water ( 4 x 5 mL) and dried in the 
Abderhalden (80oe/5 mm Hg) for 5, h. The crude product was recrystallized (95%, 
e2HsOH) to give colorless plates of 70b, (1.18 g, 54%); mp 130-131 oe (lit89 mp 129-
1300C). 1R (KBr) 3195 (N-H), 1235 (P=O), 1190 (e-O) cm-1. lH NMR (Dee13) () 6.9 
(d, NH, 2JP-H = 17.1 Hz), 7.0-7.3 (m, 15 H, Ar-H). Be (Deel3) ppm 118.1 [d, e(4), 
5Jp_c = 7.7 Hz], 120.3 [d, e(4'), 5Jp_c = 4.7 Hz], 122.3, 125.3, 129.3 e(3), 129.7 
e(2), 138.9 [s, e(1)], 150.2 [d, C(l') 2Jp_c = 6.3 Hz); 31p (Dee13; 85% H3P04, 
external reference) ppm -6.2. Mass spectra calculated (FAB) for e18H16N03P mlz 
[M+·]: 324; Found: [324+1]+·. The 1H NMR and Be NMR spectral data have not been 
previously reported. 
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Bis(4-methylphenyl)phosphinanilide (70c).69 To a boiling solution of bis(4-
tolyl) chlorophosphate (70c, 2.02 g, 6.8 mmol) in benzene (5 mL) was added dropwise a 
solution of aniline (93, 1.27 g, 13.63 mmol) in benzene (5 mL) over a period of 15 min in 
a 2-necked, round-bottomed flask (50 mL) equipped with a condenser and an addition 
funnel. A solid formed immediately and did not change during the heating and stirring 
process (1 h) at reflux. The mixture was cooled to room temperature (1 h) and then 
filtered. The precipitate was washed with warm water (4 x 5 mL), and dried in the 
Abderhalden (80°C/5 mm Hg) for 5 h. The crude product was recrystallized (anhydrous 
C2HsOH) to give colorless plates of 70c (0.58 g, 24% ); mp 130-131 oc (lit2 mp 125°C). 
IR (K.Br) 3190 (N-H), 1240 (P=O), 1200 (C-0) cm-1. lH NMR (DCC13) B 2.2 (s, 
CH3, 3 H), 6.7 (d, NH, 2JP-H = 10.6 Hz), 6.9-7.3 (m, 13 H, Ar-H); 13C NMR 
(DCC13) ppm 118.1 [d, C(4) 5Jp_c = 7.6 Hz], 120.1 [d, C(4'), 5Jp_c =4Hz], 122.2, 
129.3 C(3), 130.1 C(2), 134.8, 139.0 [s, C(1)] 148.1 [d, C(1'), 2Jp_c = 6.6 Hz]; 31p 
(DCC13; 85% H3P04, external reference) ppm -5.8. Mass spectrum (FAB) calculated for 
C20H22N03P mlz [M+·] 353; Found: [353+ 1]+·. The lH NMR and 13C NMR spectral 
data have not been previously reported. 
4-[N -Bis(phenyl)phosphoryl]aminopyridine (71a).31 To 4-aminopyridine 
(95, 0.500 g, 5.31 mmol), triethylamine (0.74 mL, 5.31 mmol), and toluene (1.6 mL), 
was added dropwise diphenyl phosphorochloridate (94a, 1.26 g, 5.31 mmol) in toluene 
(1.1 mL) over a period of 12 minutes in a 2-necked, round-bottomed flask (50 mL) 
equipped with a condenser, a magnetic stirrer, and a septum. The mixture immediately 
turned to a semi- solid mass and .did not change during the heating process (3 h) at reflux. 
The mixture was cooled to room temperature (1 h) and filtered. The precipitate was 
washed with toluene (5 mL). The off white solid was applied to a column (silica gel, 50 g) 
which was eluted with a solvent mixture (HCC13:H3COH; 10:1). The fraction with an Rr 
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value of 0.75 on a TLe plate (Hee13:H3eOH; 10:1) was collected. Evaporation of the 
solvent gave a white solid, which was recrystallized (Hee13:ether; 2:20) to give an 
amorphous powder of 71a, (0.58 g,- 39% ); mp 172.5-173.5oe (1it31 mp 173-174oe). IR 
(KBr) 3200 (N-H), 1445 (P-Ph), 1227 (P=O) cm·l. lH NMR (Dee13) a 6.86 [dd, 2 H, 
H(3) 3JH-H = 4.9 Hz, 4JP-H = 1.4 Hz], 7.3-7.8 (m, 12 H, Ar-H), 8.0 (d, NH, 3JP-H = 
6.2 Hz); Be NMR (Dee13) ppm 113.1 [d, e(4'), 4JP-C =7Hz] 128.8 [d, e(3'), 3JP-C 
= 13.2 Hz], 130.1 [s, e(3)], 131.7 [d, e(2'), 2Jp_c = 10.2 Hz] 132.5 [d, C(l'), lJp_c = 
2.5 Hz], 148.8 [s, e(4)], 149.8 [s, e(2)]; 31p NMR (Dee13; 85% H3P04, external 
reference) ppm 19.7. Mass spectrum (FAB) calculated for e17H15N20P mlz [M+·]: 
294; Found: [294+1]+·. The lH NMR and Be NMR spectral data have not been 
previously reported. 
4-[N -Bis(phenoxy)phosphoryl]aminopyridine (7lb).24 To 4-amino-
pyridine (95, 0.500 g, 5.31 mmol), triethylamine (0.74 ml, 5.31 mmol), and toluene (1.6 
mL), was added dropwise diphenyl chlorophosphate (94b, 1.43 g, 5.31 mmol) in toluene 
(1.1 mL) over a period of 12 minutes in a 2-necked, round-bottomed flask (50 mL) 
equipped with a condenser, a magnetic stirrer and a septum. The mixture immediately 
turned into a solid mass and did not change during the heating process (3 h) at reflux. The 
mixture was cooled to room temperature (1 h) and filtered. The precipitate was washed 
with toluene (5 mL) and applied to a column (silica gel, 50 g) which was eluted with a 
solvent mixture (HCC13:H3eOH; 10:1). The solvent was evaporated to give a white 
solid, which was recrystallized (anhydrous C2HsOH), to give 7lb (0.46 g, 29%), mp 
197.5-199oe (1it24 mp 190-191 oe). IR (KBr) 3140 (N-H), 1220 (P=O), 1200 (e-O) cm-
1; lH NMR (DCC13) a 7.14 [d, 2 H, H(3), 3JH-H = 6.34 Hz], 7.2-7.4 (m, 12 H, Ar-H), 
8.4 (d, NH, 2JP-H = 5.2 Hz); Be NMR (DCC13) ppm 112.4 [d, e(2'), 3Jp_c = 2.2 Hz], 
119.9 [d, e(4'), 5Jp_c = 4.6 Hz], 125.4 [s, e(3')], 129.9 [s, e(3)], 149.6 e(4), 149.7 
e(2), 150.1-150.4 (broad); 3lp (DCC13; 85% H3P04, external reference) ppm -7.9. 
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Mass spectrum (FAB) calculated for C17H 15N203P m/z [M+·]: 326; Found: 
[326+ 1]+.. The 1 H NMR and 13C NMR spectral data have not been previously reported. 
4-[N-Bis(4-methylphenoxy)phosphoryl]aminopyridine (71c).24 To 4-
aminopyridine (95, 0.500 g, 5.31 mmol), (0.74 ml, 5.31 mmol) of triethylamine, and 
toluene (1.6 mL), was added dropwise bis(4-tolyl) chlorophosphate (94c, 1.57 g, 5.31 
mmol) in toluene (1.1 mL) over a period of 12 minutes in a 2-necked, round-bottomed 
flask (50 mL) equipped with a condenser, a magnetic stirrer, and a septum. The mixture 
quickly turned to a semi-solid mass and did not change during the heating process (3 h) at 
reflux. The mixture was cooled to room temperature (1 h) and filtered. The precipitate 
was washed with toluene (5 mL). The off white solid was applied to a column (silica gel, 
50 g) which was eluted with a solvent mixture (HCC13:H3COH; 30:1). The solvent was 
evaporated to give a white solid, which was recrystallized (anhydrous C2HsOH) to give 
colorless flakes (0.92 g, 48%) of 71c, mp 226-227°C (Iit24 mp 215-216°C). IR (KBr) 
3110 (N-H), 1225 (P=O) 1210 (C-0) cm-1; 1H NMR (DMSO-d6) () 2.3 (s, CH3, 6 H), 
7.1-7.2 (m, 12 H, Ar-H), 8.3 (d, NH, 2JP-H = 5.4 Hz); 13C NMR (DMSO-d6) ppm 20.1 
(d, CH3, 6Jp_c = 2.1 Hz), 112.3 [d, C(2'), 3Jp_c = 8.1 Hz), 119.6 [s, C(3')], 119.7 [s, 
C(4')], 130.2 [s, C(2')], 134.0 [s, C(3)], 147.5 [d, C(4), 2Jp_c = 6.4 Hz)], 150.3 [d, 
C(1') 4Jp_c = 1.4 Hz]; 31p NMR (DMSO-dt;; 85% H3P04, external reference) ppm -41.1. 
Mass spectrum (FAB) calculated for C19H19N203P mlz [M+·]: 354; Found: [354+ 1]+·. 
The 1H NMR and 13C NMR spectral data have not been previously reported. 
4-[N -Bis(phenoxy)phosphoryl]aminoquinaldine (72b). To a boiling 
solution of 4-aminoquinaldine (96, 1.0 g, 6.32 mmol), triethylamine (1.76 mL, 12.64 
mmol) and toluene (2 mL) was added dropwise a solution of diphenyl chlorophosphate 
(94b, 1.69 g, 6.32 mmol) in toluene (1.2 mL) over a period of 12 min in a 2-necked, 
round-bottomed flask (50 mL) equipped with a condenser and a magnetic stirrer. A solid 
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was gradually formed and did not change during the heating process (4 h) at reflux. The 
reaction mixture was cooled to room temperature (1 h) and filtered The filtrate was 
evaporated to obtain a yellow oil, which was placed on a column (silica gel, 30 g) which 
was eluted with a solvent mixture (HCC13:H3COH; 10: 1). The fraction with an Rr value 
of 0.7 was collected and evaporated to afford a white foamy solid which was washed with 
ether (20 mL), and filtered. The precipitate was recrystallized (benzene) to give an 
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amorphous powder of 72b (0.38 g, 15%); mp 159-160 C. IR (KBr) 3260 (N-H), 1225 
(P=O), 1200 (C-0) cm·l; lH NMR (DMSO-d6) o 2.5 (s, CH3, 3 H), 6.9-7.7 (m, 15 H, 
Ar-H), 8.2 (d, NH, 2JP-H = 7.9 Hz); 13C NMR (DMSO-d6) ppm 19.6 (s, CH3), 107.7 
[d, C(3) 3Jp_c = 2.1 Hz], 120.1 [d, C(3'), 4Jp_c = 4.7 Hz], 123.7, 124.4, 125.0 [d, 
C(4'), 5Jp_c = 4.1 Hz], 129.4 [s, C(2')], 132.1, 132.2, 138.7, 150.2 [s, C(4)], 151.7 [d, 
C(1') 2Jp_c = 3.3 Hz], 164.7 [s, C(2)]; 31p NMR (DMSO-d6; 85% H3P04, external 
reference) ppm-0.6. Mass spectrum (FAB) calculated for C22H19N203P mlz [M+·]: 
390.4; Found: [390+1]+·. Anal. Calcd for C22H19N203P: N, 7.17; P, 7.93. Found: 
N, 7.11; P, 7.90. 
4-[N -Bis(4-methylphenoxy)phospboryl]aminoquinaldine (72c). To a 
boiling solution of 4-aminoquinaldine (96, 1.0 g, 6.32 mmol), triethylamine (1.76 mL, 
12.64 mmol) and toluene (2 mL) was added dropwise a solution of bis(4-tolyl) 
chlorophosphate (94c, 1.87 g, 6.32 mmol) in toluene (1.2 mL) over a period of 12 min in 
a 2-necked, round-bottomed flask (50 mL) equipped with a condenser and a magnetic 
stirrer. A solid was gradually formed and did not change during the heating process ( 4 h at 
reflux). The reaction mixture was cooled to room temperature (1 h) and filtered. The 
filtrate was evaporated to afford a yellow oil which placed on a column (silica gel, 55 g) 
and eluted with a solvent mixture (HCC13:H3COH; 20:1). The fraction with an Rrvalue 
of 0.54 was collected and evaporated to afford a foamy solid which was washed with ether 
to give an off-white solid. Filtration and recrystallization (benzene:ether) gave (0.52 g, 
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20%) of white plates of 72c mp 180-181 °C. IR (KBr) 3260 (N-H), 1225 (P=O), 
1200 (C-0) cm-1; 1H NMR (DMSO-d6) o 2.2 (s, CH3 1, 6 H), 2.4 (s, CH3, 3 H), 6.9-7.7 
(m, 13 H, Ar-H), 8.2 (d, NH, 2JP-H = 8.24 Hz); 13C NMR (DMSO-d6) ppm 19.6 (s, 
CH3), 20.1 (d, CH3 1 , 6Jp_c=2.5 Hz), 107.6 [s, C(3)], 117.9, 117.9, 119.8 [d, C(3'), 
2 I 1 Jp_c = 4.6 Hz], 124.3, 125.1, 129.6 [s, C(2 )], 132.1, 132.1, 132.6 [s, C(4 )], 138.6, 
149.5 [d, C(l'), 2Jp_c = 3.2 Hz], 149.9 [s, C(4)], 164.4 [s, C(2)]; 31p NMR (DMSO-d6; 
85% H3P04, external reference) ppm -1.5. Mass spectrum (FAB) calculated for 
C24H23N203P mlz [M+·]: 418; Found: [418+1]+·. Anal. Calcd for C24H23N203P: N, 
6.69; P, 7.40. Found: N, 6.44; P, 7.24. 
N6-Bis(phenyl)phosphinyladenine (73). To a boiling suspension of adenine 
(1, 0.50 g, 3.7 mmol) and 10 mL of anhydrous pyridine was added dropwise diphenyl-
phosphinic chloride (94a, 2.65 g, 11.2 mmol) over a period of 12 minutes in a 2-necked, 
round-bottomed flask (50 mL) equipped with a condenser and a magnetic stirrer. The 
reaction mixture was heated at reflux (1 h) during which time the mixture turned a clear 
yellow solution. The solution was cooled to room temperature (1 h), and the solvent was 
evaporated at reduced pressure (60.C/5 mm Hg). The residual pyridine was co-evaporated 
with benzene (3 x 4 mL) to give a thick, yellow oil which was treated with 1 M NaHC03 
to pH - 8 which resulted in the precipitation of a white solid. This solid was filtered and 
washed thoroughly with H20 (50 mL). The precipitate was dried in the Abderhalden 
(80.C/5 mm Hg) for 24 h over P20s to give an off-white solid which was repeatedly 
recrystallized (H20) to give an amorphous powder of 73 (0.21g, 16%); mp 231-233·c. 
IR (KBr) 3460-3400 (bs, N-H), 1445 (P-Ph), 1195 (P=O) cm-1. lH NMR (DMSO-d6) o 
3.4 (bs, NH), 7.5 (m, 6 H, Ar-H), 7.8 (m, Ar-H), 8.18 [s, 1 H, H(2)], 8.36 [s, 1 H, 
H(8)]; 13C NMR (DMSO-d6) ppm; Ar-C: 128.4, 131.6, 132.8, 134.6; bs, adenine-C: 
142.4-149.4; 31p NMR (DMSO-d6; 85% H3P04, external reference) ppm aroundl8.3 
(broad signal) Mass spectrum (FAB) calculated for C17H14NsOP m/z [M+·]: 335; 
75 
Found: [335+1]+. and [417+1]+·, corresponding to the product (73) and the phenyl 
pyrophosphate (99a), respectively. An experiment conducted with the same concentration 
of reactants but for a longer time at reflux (6 h) resulted in a 10% reduction in the yield of 
73. Attempts to purify the product 73 included sublimation, column chromatography, and 
HPLC; however, none of these methods was successful. 
TLC analysis of the crude product (HCCl3:H3COH; 10:1) indicated the presence of 
two compounds; this observation did not change after the above mentioned attempts to 
purify 73. The 31p NMR spectrum indicated the presence of two signals in the form of a 
broad signal. The estimated ratio of peaks was 10:3. Phenyl pyrophosphate is 
known20,70 and the observed IR spectrum had bands at 1440, 1240, 1120, 1110 cm·l 
(lit70 IR 1440, 1245, 1130, 1110 cm-1). 
N6-Bis(phenoxy)phosphinyladenine (74). To a boiling suspension of adenine 
(1, 0.300 g, 2.22 mmol) and 7 mL of anhydrous pyridine was added dropwise diphenyl 
chlorophosphate (94b, 0.565 g, 2.22 mmol) over a period of 12 minutes in a 2-necked, 
round-bottomed flask (50 mL) equipped with a condenser and a magnetic stirrer. The 
reaction mixture was heated (1 h), at reflux during which time the mixture turned to a clear 
yellow solution. The mixture was cooled to room temperature (1 h), and the solvent was 
evaporated at reduced pressure (60°C/5 mm Hg). The residual pyridine was co-evaporated 
with benzene (3 x 4 mL) to give a thick yellow oil which was dissolved in HCC13 (3 mL) 
and applied to a column (silica gel, 20 g) which was eluted with a solvent mixture 
(HCC 13:H3COH; 10:1). The fraction with an Rr value of 0.36 was collected. 
Evaporation of the solvent gave a foamy solid (0.4 g, 50%) which was recrystallized by 
the diffusion method (HCC13:ether; 2:20) to give an amorphous powder of 74 (0.10 g, 
12.2%); mp 118.5-120.0"C. IR (KBr) 3130-3090 (N-H), 1240 (P=O), 1200 (C-0) cm·l. 
lH NMR (DMSO-d6) o 7.17-7.39 (m, 12 H, Ar-H and NH), 8.37-8.36 [bs, 2 H, H(2) 
and H(8)]; 13C NMR (DMSO-d6) ppm 120.2 [d, C(4'), 5Jp.c = 4.J Hz); Ar-C: 124.5, 
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124.8, 129.7; bs, adenine-C: 150.4-150.6; 31p NMR (DMSO-d6; 85% H3P04, external 
reference) ppm- 7.9. Mass spectrum (FAB) calculated for C17H14Ns03P m/z [M+·]: 
367; Found: [367+1]+. and [482+1]+·, corresponding to the product 74 and the 
pyrophosphate 99b, respectively. UV of 74: Amax [H3COH] 208, 268 (sh 263, 283). 
loge: 4.33, 3.99 (3.99, 3.89). Anal. Calcd for C17H14Ns03P (74): C, 55.58; H, 3.84; 
P, 8.43. Found: C, 55.67; H, 3.82; P, 8.52. 
N'-Bis(2-methylphenoxy)phosphinyladenine (75). To a boiling suspension 
of adenine (1, 0.200 g, 1.48 mmol) and 5 mL of anhydrous pyridine was added dropwise 
di-(2-tolyl) chlorophosphate (94d, 0.878 g, 2.96 mmol) over a period of 12 minutes in a 
2-necked, round-bottomed flask (50 mL) equipped with a condenser and a magnetic 
stirrer. The reaction mixture was heated (1 h) at reflux during which time the mixture 
turned to a clear yellow solution. The solution was cooled to room temperature (1 h), and 
the solvent was evaporated at reduced pressure (60°C/5 mm Hg). The residual pyridine 
was co-evaporated with benzene (3 x 4 mL) to give a thick yellow oil which was 
dissolved in HCC13 (10 mL). This solution was washed with H20 (5 x 10 mL), dried 
(Na2S04, 5 h) and filtered. Evaporation of the solvent gave a semi-solid which was 
triturated with ether (30 mL) to give a precipitate which was filtered and recrystallized by 
the diffusion method [HCC13 (10 mL):H3COH (1 mL):hexane (-7 mL)] to give small 
white plates of75 (0.28 g, 48.3%); mp 205-206.5°C. IR (KBr) 3190-3012 (N-H), 1210 
(C-0), 1235 (P=O) cm-1. lH NMR (DMSO-d6) o 2.2 (s, CH3, 6 H), 7.1-7.3 (m, 10 H, 
Ar-H, and NH), 8.4 [bs, 2 H, H(2) and H(8)]; 13C NMR (DMSO-d6) ppm 16.2 (s, CH3); 
Ar-C: 123.1, 127.8, 130.1, 132.3, 132.4, 134.4; bs, adenine-C: 143.5, 149.2, 151.2; 
3lp NMR (DMS0-£16; 85% H3P04 external reference) ppm -8.3. Mass spectrum (FAB) 
calculated for C19H1sNs03P m/z [M+·]: 395; Found: [395+1]+ and [538+1]+·, 
corresponding to the product 75 and the pyrophosphate 99c, respectively. Anal. Calcd 
for C19H1&Ns03P (75): N, 17.71; P, 7.83. Found: N, 17.74; P, 7.48. 
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9-(2'-llydroxyethyl)adenine (76).52 In a 100 mL, 2-necked, round-bottomed 
flask equipped with a condenser and a magnetic stirrer was placed adenine (1, 1.4 g, 0.01 
mol), freshly distilled DMF (40 mL), NaOH (0.015 g), and ethylene carbonate (1.0 g, 
0.01 mol). The mixture became a clear solution during the heating process (1 h) at reflux. 
The solution was cooled to room temperature (1 h), and the solvent was evaporated at 
reduced pressure (50°C/10 mm Hg) to give a white solid which was recrystallized (95%, 
C2H50H) to give colorless plates of76 (0.95 g, 53%); mp 240.5-241.5oC (lit52 mp 238-
2390C). IR (KBr) 3240-3080 (N-H and 0-H), 1680 (C=N), 1605 (C=C, aromatic), 1200 
(C-0) cm-1. 1H NMR (DMSO-d6) 8 3.74 [q, 2 H, H(2'), 3J:H-H = 5.5 Hz], 4.2 [t, 2 H, 
H(1'), 2 H, 3JH-H = 5.5 Hz], 5.02 (t, OH, 1 H), 7.21 ,(bs, NH2), 8.08 [s, 1 H, H(2), ], 
8.15 (s, H(8) 1 H); 13C NMR (DMSO-d6) ppm 45.62 [C(2')], 59.17 [C(l')], 118.62 
[C(5)], 141.24 [C(8)], 149.45 [C(4)], 152.16 [C(2)], 155.83 [C(6)]. The 1H NMR and 
13C NMR spectral data have not been previously reported. 
9-(2'-Chloroethyl)adenine (77).52 In a 2-necked, round-bottomed flask (25 mL) 
equipped with a condenser and a lllD:gnetic stirrer was placed alcohol 76 (0.52 g, 2.9 
mmol) and thionyl chloride (5 mL, 0.06 mol). The mixture was heated over a water bath 
( 40 min) during which time the solution turned into an orange slush. The mixture was 
cooled to room temperature (30 min), and the excess thionyl chloride was evaporated 
under reduced pressure (50°C/10 mm Hg) to give a solid which was dried under reduced 
pressure (80°C/l mm Hg) for 2 h. The orange solid was dissolved in 5% Na2C03 (10 
mL) solution and the addition of 5% Na2C03 was continued until a precipitate formed. 
The precipitate was filtered off and dried in the Alxlerhalden (80°C/5 mm Hg), for 5 h and 
recrystallized (anhydrous C2H50H) to give colorless needles of 77 (0.28 g, 50%); mp 
202-203oC (lit52 mp 204-205°C). IR (KBr) 3340-3115 (HN-H), 1653 (C=N) cm-1; 1H 
NMR (DMSO-d6) 8 4.08 [t, 2 H, H(2'), 3JH-H = 5.8 Hz], 4.5 [t, 2 H, H(1'), 3JH-H = 5.8 
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Hz), 7.3 (bs, NH2), 8.17 [s, 1 H, H(2)], 8.19 [s, 1 H, H(8)]; nc NMR (DMSO-d6) ppm 
42.7 [C(2')], 44.7 [C(1')], 118.6 [C(5)], 140.9 [C(8)], 149.4 [C(4)], 152.4 [C(2)], 
155.9 [C(6)]. The lH NMR and Be NMR spectral data have not been previously 
reported. 
9-[2'-0-Bis(phenyl)phosphinylJethyladenine (78) To a boiling suspension 
of alcohol 76 (0.385 g, 2.148 mmol) ~nd 7 mL of anhydrous pyridine was added 
dropwise diphenyl phosphorochloridate (94a, 0.610 g, 2.58 mmol) over a period of 12 
minutes in a 2-necked, round-bottomed flask (50 mL) equipped with a condenser and a 
magnetic stirrer. The reaction mixture was heated (1 h) at reflux during which time the 
mixture turned to a clear yellow solution. The solution was cooled to room temperature (1 
h), and the solvent was evaporated at reduced pressure (60°C/5 mm Hg). The residual 
pyridine was co-evaporated with benzene (3 x 4 mL) to give a thick yellow oil which was 
dissolved in HCC13 (2.5 mL) and applied to a column (silica gel, 10 g) which was eluted 
with a solvent mixture (HCCl3:H3COH; 10:1). The fraction with an Rrvalue of 0.52 was 
collected. Evaporation of the solvent gave a white, foamy solid which was washed with 
ethyl acetate and filtered; the precipitate was recrystallized using the diffusion method 
(C2HsOH:ether; 1:25) to give crystalline 78 (0.126 g, 42%), mp 199-200°C. IR (KBr) 
3300- 3120 (HN-H) 1448 (P-Ph), 1245 (P=O), 1030 (P-0-C) cm-1. lH NMR (DMSO-
d6) 0 4.2 [m, 2 H, H(2')], 4.5 [t, 2 H, H(1'), 3JH-H = 4.8 Hz], 7.3 (s, NH2), 7.3-7.6 
(m, 10 H, Ar-H), 8.1 (s, 1 H, H(2)], 8.2 [s, 1 H, H(8)]; 13C NMR (DMSO-d6) ppm 40.2 
[C(l')], 43.4 [d, C(2'), 2Jp_c = 8 Hz]. 118.7 [C(5)]; Ar.,.C: 128.4, 128.6, 129.9, 130.8, 
130.9, 131.7, 132.2, 132.2; 141.0 [C(8)], 149.5 [C(4)], 152.3 [C(2)], 155.9 [C(6)]; 31p 
NMR (DMSO-d6; 85% H3P04 external reference) ppm 31.67. Mass spectrum (FAB) 
calculated for C19HtsNs02P m/z [M+·]: 379; Found: [379+1]+·. Anal. Calcd for 
C19HtsNs02P: N, 18.46; P, 8.16. Found: N, 18.33; P, 8.20. 
79 
9-(2 '-Chloroethyi)-N6- bis(phenoxy)phosphinyladenine (79). Method 
A: To a boiling suspension of alcohol 76 (0.200 g, 1.11 m'Tlol) and 10 mL of anhydrous 
pyridine was added dropwise diphenyl chlorophosphate (94b, 0.93 g, 3.46 mmol) over a 
period of 12 minutes in a 2-necked, round-bottomed flask (50 mL) equipped with a 
condenser and a magnetic stirrer. The reaction mixture was heated (1 h) at reflux during 
which time the mixture turned to a clear yellow solution. The solution was cooled to room 
temperature (1 h), and the solvent was evaporated at reduced pressure (60°C/5 mm Hg). 
The residual pyridine was co-evaporated with benzene (3 x 4 mL) to give a thick, yellow 
oil which was dissolved in HCC13 ( 4 mL) and purified by means of flash-chromatography 
' 
on alumina (20 g) using a solvent mixture of (HCCl3:H3COH; 30:1). The solvent was 
evaporated to give a yellow oil which was triturated with ether to give a white solid. The 
solid was filtered and recrystallized using the diffusion method (HCC13:ether; 2:20) to 
give an amorphous powder of79 (0.2 g, 41%), mp 175-176.5°C. IR (KBr) 3100 (N-H), 
1218 (P=O), 1194 (C-0) cm-1. lH NMR (DCCl3) o 3.9 [t, 2 H, H(2'), 3JH-H = 5.6 Hz)], 
4.5 [t, 2 H, H(1'), 3JH-H = 5.7 Hz], 7.1-7.3 (m, 10 H, Ar-H), 8.05 [s, 2 H, H(2) and 
H(8)], 8.7 (bs, 1 H, NH); 13C NMR (DCCl3) ppm 42.0 [C(2')], 45.8 [C(l')] 120.7, 
C(5); Ar-C: 121.4, 125.5, 129.7, 150.9; 144.1 C(8), 150.2 C(4), 151.1 C(2), 151.2, 
C(6); 31p NMR (DCCl3; 85% H3P04, external reference) ppm -8.91. Mass spectrum 
(FAB) caculated for C19H17ClNs03P mlz [M+·]: 428; Found: [428+1]+·. Anal. Calcd 
for Ct9H17ClNs03P: N, 16.29; P, 7.21. Found: N, 16.21; P, 7.13. 
Method B: To a boiling suspension of chloride 77 (0.065 g, 0.23 mmol) and 2 mL 
of anhydrous pyridine was added dropwise diphenyl chlorophosphate (94b, 2.65 g, 11.2 
mmol) over a period of 12 minutes in a 2-necked, round-bottomed flask (50 mL) equipped 
with a condenser and a magnetic stirrer. The reaction mixture was heated (1 h) at reflux 
during which time the mixture turned to a gray solution. The solution was cooled to room 
temperature (1 h) and filtered, and the solvent was then evaporated at reduced pressure 
(60oC/5 mm Hg). The residual pyridine was co-evaporated with benzene (3 x 4 mL) to 
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give a thick, yellow oil which was dissolved in HCC13 (2 mL) and applied to a column 
(silica gel, 10 g). The fraction with an Rr value of 0.44 was collected. The solvent was 
evaporated to give a white solid which was recrystallized by the diffusion method 
(HCC13:ether; 2:20) to give crystalline product 79 (0.075 g, 53%), mp 175-176.5°C. 
9-(2'-Chloroethyi)-N6-bis(4-tolyl)phosphinyladenine (80). To a boiling 
suspension of alcohol 76 (0.200 g, 1.11 mmol) and 4.5 mL of anhydrous pyridine was 
added dropwise bis(4-tolyl) chlorophosphate (94c, 1.021 g, 3.44 mmol) over a period of 
12 minutes in a 2-necked, round-bottomed flask (50 mL) equipped with a condenser and a 
magnetic stirrer. The reaction mixture was heated (1 h) at reflux during which time the 
mixture turned into a clear yellow solution. The solution was cooled to room temperature 
(1 h), and the solvent was evaporated at reduced pressure (60°C/5 mm Hg). The residual 
pyridine was co-evaporated with benzene (3 x 4 mL) to give a thick, yellow oil which was 
dissolved in HCCl3 and purified by means of flash chromatography on alumina (40 g) 
using a solvent mixture of (HCC13:H3COH; 30:1). The solvent was evaporated to give a 
yellow oil which was triturated with ether to give a white solid which was filtered. The 
precipitate was recrystallized using the diffusion method (HCCl3:ether; 2:20) to give an 
amorphous powder of 80 (0.06 g, 16%), mp 152.5-154°C. IR (KBr) 3100 (N-H), 1225 
(P=O), 1200 (C-0) cm-1. lH NMR (DCC13) 8 2.27 (s, CH3, 6 H), 3.9 [t, 2 H, H(2')] 
4.5 [t, 2 H, H(1')], 7.06-7.21 (m, 8 H~ Ar-H), 8.02 [s, 2 H, H(2) and H(8)], 8.7 (s, 
NH), 13C NMR (DCC13) ppm 20.7 (d, CH3, 6 H, 6Jp_c = 5.6 Hz), 42.0 [C(2')], 45.8 
[C(l')], 119.9 [C(5)]; Ar-C: 120.4, 120.4, 130.2, 135.1, 148.1; 143.8 [C(8)], 150.9 
[C(4)], 151.2 [C(2)], 152.0 [d, C(6), 2Jp_c = 5.5 Hz]; 31p NMR (DCC13: 85% H3P04 
external reference) ppm -8.97. Mass spectrum (FAB) calculated for C21H2tClNs03P mlz 
[M+·]: 457; Found: [457+1]+·. Anal. Calcd for C21H2tClNs03P: N, 15.29; P, 6.76. 
Found: N, 15.08; P, 6.76. 
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Attempted Preparation of 9-(2'-0-Phenylchlorophosphinyl)ethyl-
adenine. To a boiling suspension of alcohol 76 (0.250 g, 1.4 mmol) and 8 mL of 
anhydrous pyridine was added dropwise phenylphosphonic dichloride (103, 0.273 g, 1.4 
mmol) over a period of 12 minutes in a 2-necked, round-bottomed flask (50 mL) equipped 
with a condenser and a magnetic stirrer. The reaction mixture was heated (1 h) at reflux 
during which time the mixture turned into a clear yellow solution. The solution was cooled 
to room temperature (1 h), and the solvent was evaporated at reduced pressure (60.C/5 mm 
Hg). The residual pyridine was co-evaporated with benzene (3 x 4 mL) to give a thick 
yellow oil. TLC analysis (HCCl3:H3COH; 10: 1) indicated that the major fraction was 
identical to that of 2'-chloroethyladenine (77). The oil was dissolved in HCC13 (2.5 mL) 
and applied to a column (silica gel, 10 g) which was eluted with a solvent mixture 
(HCC13:MeOH, 10:1) to give the adenine derivative 77 (29%) and other tar-like material 
which was intractable. 
Attempted Preparation of 9-(2'-0 -Phenoxychlorophosphinyl)ethyl-
adenine. To a boiling suspension of alcohol 76 (0.250 g, 1.4 mmol) and 8 mL of 
anhydrous pyridine was added dropwise phenyl dichlorophosphate (104, 0.295 g, 1.4 
mmol) over a period of 12 minutes in a 2-necked, round-bottomed flask (50 mL) equipped 
with a condenser and a magnetic stirrer. The reaction mixture was heated (1 h) at reflux 
during which time the mixture turned into a clear yellow solution. The solution was cooled 
to room temperature (1 h), and the solvent was evaporated at reduced pressure (60.C/5 mm 
Hg). The residual pyridine was co-evaporated with benzene (3 x 4 mL) to give a thick 
brown oil which upon TLC analysis, indicated the presence of the adenine chloride 
derivative 77. The oil was dissolved in HCC13 (2.5 mL) and applied to a column (silica 
gel, 10 g) which was eluted with a solvent mixture (HCC13:H3COH; 10:1) to give the 
adenine derivative 77 (39%, mp 202-203.C) along with tar-like material that could not be 
purified. 
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9-(2'-0 -Phenylphenoxyphosphinyl)ethyladenine (81). To a boiling 
suspension of alcohol 76 (0.400 g, 2.23 mmol) and 9 mL of anhydrous pyridine was 
added dropwise phenyl phenylphosphonochloridate (105, 0.648 g, 2.56 mmol) over a 
period of 10 minutes in a 2-necked, round-bottomed flask (50 mL) equipped with a 
condenser and a magnetic stirrer. The reaction mixture was heated (1.5 h) at reflux during 
which time the mixture turned into a clear yellow solution. The solution was cooled to 
room temperature (1 h). A small amount of precipitate was filtered off, and the solvent 
was evaporated at reduced pressure (60"C/5 mm Hg). The residual pyridine was co-
evaporated with benzene (3 x 3 mL) to give a thick yellow oil which was dissolved in 
HCC13 (2.5 mL) and applied to a column (silica gel, 9 g) which was eluted with a solvent 
mixture (HCC13:H3COH; 10:1). The fraction with an Rr value of 0.53 was collected. 
The solvent was evaporated to give a yellow oil which was triturated with anhydrous ether 
to give an off-white solid which was recrystallized by the diffusion method using 
(HCCl3:ether; 1:9) to obtain an amorphous powder of 81 (0.44 g, 50%), mp 145.5-
1460C. IR (KBr) 3100 (broad, N-H), 1447 (P-Ph), 1255 (P=O), 1200 (P-0-C) cm-1. 
lH NMR (DMSO-d6) B 3.2-3.8 (bm, 2 H, NH2), 4.53 (b, 4 H, CH2-CH2), 6.99-7.64 
(m, 10 H, Ar-H), 8.44 and 8.46 [both s, 2 H, H(2), H(8)]; 13C NMR (DMSO-d6) ppm 
44.05 [d, C(2'), 2Jp_c = 6.7 Hz], 64.13 [d, C(l'), 3Jpoc = 5.6 Hz], 117.9 [C(5)], 120.0 
(d), 125.0, 125.2, 127.05~ 128.7 (d), 129.7, 131.33 (d), 133.2 (d), 143.9, 145.3, 
148.6, 149.7(d), 150.6 (Ar-C); 31p NMR (DMSO-d6; 85% H3P04 external reference) 
ppm 15.32.' Mass spectrum (FAB) calculated for Ct9H1sNs03P m/z [M+·]: 395; Found: 
[395+ 1]+·. Anal. Calcd for Ct9HtsNs03P·2.5 H20: N, 15.90; P, 7.03. Found: N, 
15.76; P, 7.14. Anal. Calcd for Ct9H1sNs03P·l.5H20: N, 16.58; P, 7.33; and for 
Ct9H1sNs03P·H20: N, 16.94; P, 7.49. 
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9-(2'-Azidoethyl}adenine (82). A mixture of chloride 77 (0.400 g, 2.024 
mmol), sodium azide (0.395 g, 6.072 mmol) and DMSO (4 mL) was heated with 
continuous stirring at 80oC (4 h) in a jacketed flask (benzene), equipped with a condenser 
and a gas inlet . The mixture became cloudy within the frrst 20 min, and, after 4 h, the 
mixture was cooled to room temperature (30 min). Water (5 mL) and HCCl3 (8 mL) were 
added and the organic layer was separated. The aqueous layer was extracted with HCCl3 
(3 x 5 mL) during which time a solid was formed in the organic layer. The solid was 
flltered off to give 80 mg of a white solid [IR (KBr) indicated the presence of an N3 
group at 2100 cm-1],76 The HCCl3 layers were washed with brine (2 x 6 mL) and dried 
(MgS04, 5 h). Evaporation of the solvent gave a white solid (70 mg) which had an IR 
spectrum identical to that for the previous solid isolated. Further extractions of the 
aqueous layer using warm HCCl3 (4 x 5 mL) gave an additional crop of a white solid 
(0.037 g). The combined solids were recrystallized (HCCl3) to give white needles of 82 
(0.18 g, 36%), mp 182.5-183.5°C. IR (KBr) 3300-3100 (broad, HN-H), 2100 (N3) 
cm-1. lH NMR (DMSO-d6) o 3.80 [t, 2 H, H(2')], 4.35 [t, 2 H, H(1 ')], 7.26 (b, 2 H, 
NHz), 8.17 [b, 2 H, H(2) and H(8)]; 13C NMR (DMSO-d6) ppm 42.35.[C(2')], 49.61 
[C(1 ')], 118.61 [C(5)], 140.7 [C(8)], 149.5 [C(4)], 152.43 [C(2)], 155.03 [C(6)]. Mass 
spectrum (FAB) calculated for C7HsNs m/z [M+·]: 204.0871; Found: 204.0871. Anal. 
Calcd for C7HgNg: C, 41.17; H, 3.95; N, 54.87. Found: C, 40.95; H, 3.97; N, 54.85. 
9-(2'-Azidoethyi)-N'-bis(phenoxy)phosphinyladenine (83). A mixture of 
chloride 79 (0.150 g, 0.35 mmol), sodium azide (0.068 g, 1.05 mmol) and DMSO (1.5 
mL) was heated with continuous stirring at 80oC (4.5 h) in a jacketed flask (benzene), 
equipped with a condenser and a gas inlet. The pale yellow solution became cloudy within 
the first 50 min of the reaction. The mixture was cooled to room temperature over a period 
of 30 min. Water (2 mL) and HCCh (3 mL) were added and the organic layer separated. 
The aqueous layer was extracted with HCCl3 (3 x 2 mL). The combined HCCl3 layers 
84 
were washed with brine (2 x 3 mL) and dried (MgS04, 4 h). Evaporation of the solvent 
gave a pale yellow oil which was triturated with anhydrous ether to give a white solid 
(0.065 g, 43%) which was recrystallized (HCCI3:ether; 3:20) by the diffusion method to 
yield white plates of 83 (55 mg, 37%); mp 138-139°C. IR (KBr) 3100 (broad, N-H), 
2100 (N3), 1210 (P=O) cm-1. 1H NMR (DCCl3) a 3.77 [t, 2 H, H(2')], 4.32 [t, 2 H, 
H(1')], 8.7 (bs, 1 H, NH), 8.03 [bs, 2 H, H(2) and H(8)]; 13C NMR (DCCl3) ppm 43.16 
[C(2')], 50.03 [C(l')], 120.67 [C(5)], 143.8 [C(8)], 150.93. [C(4)], 151.12 [C(2)], 
152.2 [C6)]; (Ar-C): 125.4, 129.6, 150.2, 150.2; 31p NMR (DCCl3); 85% H3P04 
external reference) ppm -9.27. Mass spectrum (FAB) calculated for C19H17Ns03P m/z 
[M+·]: 436.1161; Found: [436+1]+·. Anal. Calcd for C19H17Ns03P: N, 25.68; P, 
7.07. Found: N, 25.95; P, 7.14. 
9-(2'-Azidoethyi)·N'-bis(4-methylphenoxy)phosphinyladenine (84). A 
mixture of chloride 80 (0.303 g, 0.663 mmol), sodium azide (0.123 g, 1.98 mmol), and 
DMSO (3 mL) was heated with continuous stirring at 80°C (4.5 h) in a jacketed flask 
(benzene), equipped with a condenser and a gas inlet. The pale yellow solution became 
cloudy within the first 50 min. of the reaction. The mixture was cooled to room 
temperature over a period of 30 minutes. Water (4 mL) and HCCh (6 mL) were added 
and the organic layer separated. The aqueous layer was extracted with HCCl3 (3 x 4 mL). 
The combined HCCl3 layers were washed with brine (2 x 6 mL) and dried (MgS04, 4 h). 
The solvent was evaporated to give a pale yellow oil which, upon trituration with cold 
ether, did not yield a white solid. Anhydrous ether (1 mL) was added to the residue, and 
the mixture was placed in the refrigerator overnight to give a white solid which was 
recrystallized (HCCl3:ether; 8:20) by the diffusion method. A white amorphous powder of 
84 (0.12 g, 39%) was isolated; mp 109.5-111 °C. IR (KBr) 3105 (broad, N-H), 2100 
(N3), 1230 (P=O) cm-1. lH NMR (DCCl3) a 3.78.[t, 2 H, H(2')], 4.30 [t, 2 H, H(1')], 
8.7 (b, 1 H, NH), 8.00 [b, 2 H, H(2) and H(8)]; 13c NMR (DCCl3) ppm 20.74 (CH3), 
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43.2[C(2')], 50.1 [C(l')], 120.34, 120.4 [C(5)], 130.16, 135.04, 143.7, [C(8)], 148.03, 
148.12, [C(4)], 151.19 [C(2)], 152.2.[C(6)], (Ar-C); 31p NMR (DCCl3); 85% H3P04 
external reference) ppm -9.23. Mass spectrum (FAB) calculated for C21H2tNs03P m/z 
[M+·]: 464.1474; Found: [464+1]+·. Anal. Calcd for C21H21Ns03P: N, 24.13; P, 
6.67. Found: N, 24.54; P, 6.57. 
9-[2'-(N-2-Methylpyridinyl)]aminoethyladenine (85). Method A: In a 2-
necked, round-bottomed flask (50 mL) equipped with a condenser and a gas inlet was 
placed freshly distilled 2-(aminomethyl)pyridine (110, 0.137 g, 1.265 mmol), 
triethylamine (0.44 mL, 3.16 mmol), and freshly distilled n-butanol (8 mL). The reaction 
mixture was stirred at room temperature for 15 min. To this mixture was added the 
chlorinated adenine derivative 77 (0.250 g, 1.265 mmol) in one portion, and the mixture 
was allowed to heat at reflux for 20 h. Progress of the reaction was followed by TLC 
[appearance of a new compound (HCCl3:H3COH; 10:1)]. The reaction mixture was 
cooled to room temperature over a period of 3 h during which time a precipitate was 
observed. The solvent was evaporated to give a semi-solid residue which was applied to a 
Chromatotron plate and eluted with a solvent mixture of (HCCl3:H3COH; 10:1). 
Collection of the appropriate fraction (2nd band) and evaporating the solvent afforded an 
off-white solid which was recrystallized (HCCl3) to give white plates of 85 (0.185 g, 54.3 
%); mp 163-164°C. IR (KBr) 3290-3100 (broad, HN-H, N-H), 1680 (C=N) cm-1. lH 
NMR (DMSO-d6) o 2.94 [t, 2 H, H(2')], 3.44 (bs, 1 H, NH), 3.8 [s, 2 H, H(3')], 4.2 [t, 
2 H, H(1')], 7.19 (bs, 2 H, NH2), 7.23-7.7 [m, 3 H, H(5'), H(6'), H(7')], 8.13 [b, 2 H, 
H(2), H(8)] 8.47 [m, 1 H, H(8')]; 13C NMR (DMSO-d6) ppm 42.87 [C(2')], 47.76 
[C(l')], 53.8 [C(3')], 118.59 [C(5)], 121.54, 121.74 [C(5'), C(6')], 136.25 [C(7')], 
141.19 [C(8)], 148.6 [C(8')], 149.49 [C(4)], 152.14 [C(2)], 155.81 [C(6)], 160.01 
[C(4')]. Mass spectrum (FAB) calculated for C13H15N7 m/z [M+·]: 269.313; Found: 
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[269+ 1]+·. Anal. Calcd for C13H15N7: C, 57.96; H, 5.61; N, 36.42. Found: C, 58.06; 
H, 5.63; N, 36.22. 
Method 8: A mixture of chloride 77 (0.350 g, 0.177 mmol), freshly distilled (bp 
54.C/2.5 mm Hg) 2-(aminomethyl)pyridine (110, 0.21 g, 1.95 mmol), and pyridine (7 
mL) was placed in a similar system as above. The mixture was heated at reflux (2.5 h) 
with stirring (magnetic). A precipitate was observed almost immediately. The mixture 
was cooled to room temperature over a period of 40 minutes and filtered. The filtrate was 
evaporated to dryness (<45.C) under reduced pressure (2.5 mm Hg) to give an orange 
solid. Traces of pyridine were co-evaporated with benzene (3 x 2 mL). The residue was 
dissolved in a minimum amount of (HCCl3:H3COH; 10: 1) and applied to a Chromatotron 
plate which was eluted with the same solvent system. The fraction with an Rr value of 
0.31 was collected, and the solvent was evaporated (<45.C) to give an off-white solid 
which was washed with ether and dried in vacuo (80.C/5 mm Hg). The isolated, off-
white solid was recrystallized (HCCl3:C2HsOH:ether; 15:1 :5) to give white plates of 85 
(0.150 g, 32%) 
9-[2'-(N-3-Methylpyridinyl)]aminoethyladenine (86). Method A: In a 
2-necked, round-bottomed flask (50 mL) equipped with a condenser and a gas inlet was 
placed freshly distilled 3-(aminomethyl)pyridine (111, 0.109 g, 1.012 mmol), 
triethylamine (0.35 mL, 2.53 mmol), and freshly distilled n-butanol (7 mL). The reaction 
mixture was stirred at room temperature for 15 min. To this mixture was added chloride 
77 (0.200 g, 1.012 mmol) in one portion, and the mixture was allowed to heat at reflux 
for 20 h. The reaction mixture was cooled to room temperature over a period of 3 h, 
during which time a precipitate was obsereved. The solvent was evaporated to give a 
semis-solid residue which was applied to a Chromatotron plate and eluted with a solvent 
mixture of (HCCI3:H3COH; 10:1). Collection of the appropriate fraction (2nd band) and 
evaporating the solvent afforded a white solid which was recrystallized (HCCl3) to give 
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white crystals of 86 (0.153 g, 56.0 %); mp 166-167·c. IR (KBr) 3290-3100 (broad, 
HN-H, N-H), 1680 (C=N) cm-1. lH NMR (DMSO-d(;) o 2.89 [t, 2 H, H(2')], 3.35 (b, 1 
H, NH), 3.72 [s, 2 H, H(3)], 4.22 [t, 2 H, H(1')], 7.19 (b, 2 H, NH2), 7.26-7.64 [m, 2 
H, H(S'), H(6')], 8.1 [b, 2 H, H(2), H(8)], 8.40-8.46 [m, 2 H, H(7') and H(8')]; 13C 
NMR (DMSO-d6) ppm 42.7 [C(2')], 47.5 [C(l')], 49.47 [C(3')], 118.58 [C(S)], 123.14 
[C(6')], 135.4 [C(5')], 135.85 [C(4')], 141.16 [C(8)], 147.76 [C(7')], 149.21 [C(8')], 
149.48 [C(4)], 152.13 [C(2)], 155.8 [C(6)]. Mass spectrum (FAB) calculated for 
C13H15N7 m/z [M+·]: 269.313; Found: [269+1]+·. Anal. Calcd for C13H15N7: C, 
57.98; H, 5.86; N, 36.42. Found: C, 57.86; H, 5.64; N, 36.42. 
Method B: A mixture of chloride 77 (0.600 g, 3.036 mmol), freshly distilled (bp 
73-74"C/1 mm Hg) 3-(aminomethyl)pyridine (111, 0.377 g, 3.5 mmol), and pyridine (8 
mL) was placed in a similar system as above. The mixture was heated at reflux (2.5 h) 
with stirring. A precipitate was observed almost immediately. The mixture was cooled to 
room temperature over a period of 40 min and filtered. Th~ filtrate was evaporated to 
dryness ( <45.C) under reduced pressure (2.5 mm Hg) to give an off-white solid. Traces 
of pyridine were co-evaporated with benzene (3 x 2 mL). The residue was dissolved in a 
minimum amount of (HCCl3:H3COH; 10:1) and applied to a Chromatotron plate which 
was eluted with the same solvent system. The fraction with an Rr value of 0.53 was 
collected, and the solvent was evaporated ( <45.C) to give a white solid which was washed 
with ether and dried in vacuo (80"C/5 mm Hg); recrystallization (HCCl3) gave a white 
powder (0.325 g, 41 %) of 86. 
9-[2'-(N -4-Methylpyridinyl)]aminoethyladenine (87). Method A: In a 
2-necked, round-bottomed flask (50 mL) equipped with a condenser and a gas inlet was 
placed freshly distilled 4-(aminomethyl)pyridine (112, 0.109 g, 1.012 mmol), 
triethylamine (0.35 mL, 2.53 mmol), and freshly distilled n-butanol (7 mL). The reaction 
mixture was stirred at room temperature for 15 min. To this mixture was added chloride 
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77 (0.200 g, 1.012 mmol) in one portion, and the mixture was allowed to heat at reflux 
for 20 h. The reaction mixture was cooled to room temperature over a period of 3 h, 
during which time a precipitate was obsereved. The solvent was evaporated to give a 
semi-solid residue which was applied to a Chromatotron plate and eluted with a solvent 
mixture of (HCCl3:H3COH; 10:1). Collection of the appropriate fraction (2nd band) and 
evaporating the solvent afforded a white solid which was recrystallized (HCCl3) to give a 
white powder of 87 (0.139 g, 50.0 %); mp 161.5-162.5°C. IR (KBr) 3290-3100 (broad, 
HN-H, N-H), 1680 (C=N) cm-1. lH NMR (DMSO-d6) o 2.89 [t, 2 H, H(2')], 3.36 (bs, 
1 H, NH), 3.73 [s, 2 H, H(3')], 4.42 [t, 2 H, H(1')], 7.2 (bs, 2 H, NH2), 7.24 [m, 2 H, 
H(5')], 8.42 [bs, 2 H, H(2), H(8)], 8.44 [d, 2 H, H(6'), 3JH-H = 1.3 Hz]; 13C NMR 
(DMSO-d6) ppm 42.84 [C(2')], 47.53 [C(l')], 50.8 [C(3')], 118.6 [C(5)], 122.73 
[C(5')], 141.19 [C(8)], 149.2 [C(4')], 149.5 [C(4)], 149.66 [C(6')], 152.0 [C(2)], 155.0 
[C(6)]. Mass spectrum (FAB) calculated for C13H1sN7 m/z [M+·]: 269; Found: 
[269+1]+·. Anal. Calcd for C13H15N7: C, 57.96; H, 5.61. Found: C, 57.99; H, 5.56. 
Method B: A mixture of chloride 77 (0.600 g, 3.036 mmol), freshly distilled (bp 
230°C) 4-(aminomethyl)pyridine (112, 0.377 g, 3.5 mmol), and pyridine (10 mL) was 
placed in a similar system as above. The mixture was heated at reflux (2.5 h) with stirring. 
A precipitate was observed almost immediately. The mixture was cooled to room 
temperature over a period of 40 minutes and filtered. The filtrate was evaporated to 
dryness ( <45°C) under reduced pressure (2.5 mm Hg) to give an orange solid. Traces of 
pyridine were co-evaporated with benzene (3 x 2 mL). The residue was dissolved in a 
minimum amount of (HCCl3:H3COH; 10: 1) and applied to a Chromatotron plate which 
was eluted with the same solvent system. The fraction with an Rr value of 0.26 was 
collected, and the solvent was evaporated ( <45°C) to give an off-white solid which was 
washed with ether and dried in vacuo (80°C/5 mm Hg); recrystallization (HCCl3) gave a 
white powder (0.370 g, 46%) of 87. 
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9-[2'-(N -2-Methylthiophene)]aminoethyladenine (88). Method A: In a 
2-necked, round-bottomed flask (50 mL) equipped with a condenser and a gas inlet was 
placed freshly distilled 2-aminothiophene (113, 0.160 g, 1.42 mmol), triethylamine (0.51 
mL, 3.55 mmol), and freshly distilled n-butanol (8 mL). The reaction mixture was stirred 
at room temperature for 15 min. To this mixture was added chloride 77 (0.280 g, 1.42 
mmol) in one portion and the mixture was allowed to heat at reflux for 20 h. The reaction 
mixture was cooled to room temperature over a period of 3 h, during which a precipitate 
was obsereved. The solvent was evaporated to give a semi-solid residue which was 
applied to a Chromatotron plate and eluted with a solvent mixture of (HCCl3:H3COH; 
10:1). Collection of the appropriate fraction (3rd band) and evaporating the solvent 
afforded a white solid which was recrystallized from HCCh to give white crystals of 88 
(0.170 g, 44.0 %); mp 192-193°C). IR (KBr) 3290-3100 (broad, HN-H, N-H), 1680 
(C=N) cm-1. lH NMR (DMSO-d6) o 2.9[t, 2 H, H(2')], 3.6 (bs, 1 H, NH), 3.69 [s, 2 
H, H(3')], 4.19 [t, 2 H, H(1')], 5.54 [bs, 1 H, H(7')], 6.18-6.37 [m, 2 H, H(5'), 
H(6')], 7.19 (bs, 2 H, NH2), 8.09 and 8.14 [both s, 2 H, H(2), H(8)]; Be NMR 
(DMSO-d6) ppm 42.66 [C(2')], 46.9 [C(l ')], 47.4 [C(3')], 118.56 [C(5)], 124.39 
[C(6')], 124.5 [C(5')], 126.43 [C(7')], 141.12 [C(8)], 144.5 [C(4')], 149.48 [C(4)], 
152.13 [C(2)], 155.79 [C(6)]. Mass spectrum (FAB) calculated for C12H14N6S m/z 
[M+·]: 274; Found: [274+1]+·. Anal. Calcd for C12H14N6S: H, 5.14; N 30.63. Found: 
H, 5.15; N, 30.26. 
Method B: A mixture of chloride 77 (0.400 g, 2.024 mmol), freshly distilled (bp 
86-87°C/2.5 mm Hg), 2-thiophenemethylamine (113, 0.252 g, 2.23 mmol), and pyridine 
(9 mL) was placed in a similar system as above. The mixture was heated at reflux (2.5 h) 
with stirring (magnetic). A precipitate was observed almost immediately. The mixture 
was cooled to room temperature over a period of 40 minutes and filtered. The filtrate was 
evaporated to dryness ( <45°C) under reduced pressure (2.5 mm Hg) to give an off-white 
solid. Traces of pyridine were co-evaporated with benzene (3 x 2 mL). The residue was 
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dissolved in a minimum amount of (HCCl3:H3COH; 15:1) and applied to a Chromatotron 
plate which was eluted with the same solvent system. The fraction with an Rt value of 
0.28 was collected, and the solvent was evaporated (<4SOC) to give an off-white solid 
which was washed with ether and dried in vacuo (80°C/5 mm Hg) to give 88 (0.104 g, 
19%). 
9-[2'-(N-2-Metbylfurfuryl]aminoetbyladenine (89). Method A: In a 2-
necked, round-bottomed flask (50 mL) equipped with a condenser and a gas inlet was 
placed freshly distilled 2-furfurylamine (114, 0.246 g, 2.53 mmol), triethylamine (0.88 
mL, 6.33 mmol), and freshly distilled n-butanol (10 mL). The reaction mixture was 
stirred at room temperature for 15 min. To this mixture was added chloride 77 (0.500 g, 
2.53 mmol) in one portion, and the mixture was allowed to heat at reflux for 20 h. The 
reaction mixture was cooled to room temperature over a period of 3 h, during which a 
precipitate was obsereved. The solvent was evaporated to give a semi-solid residue which 
was applied to a Chromatotron plate and eluted with a solvent mixture of (HCCl3:H3COH; 
10:1). Collection of the appropriate fraction (2nd band) and evaporating the solvent 
afforded an off-white solid which was recrystallized (HCC13) to give white needles of 89 
(0.290 g, 45.0 %); mp 182.5-183.5°C. IR (KBr) 3290-3100 (broad, HN-H, N-H), 1680 
(C=N) cm-1. lH NMR (DMSO-d6) o 2.93 [t, 2 H, H(2')], 3.35 (bs, 1 H, NH), 3.89 [s, 
2 H, H(3')], 4.2 [t, 2 H, H(l')], 6.93 [m, 2 H, H(5') and H(6')], 7.18 (bs, 2 H, NH2), 
7.33 [m, 1 H, H(7'), 8.11 and 8.13 [both s, 2 H, H(2), H(8)]; 13C NMR (DMSO-d6) 
ppm 42.65 [C(2')], 44.71 [C(1')], 47.4 [C(3')], 106.6 [C(6')], 110.13 [(5')], 118.57 
[C(5)], 141.1 [C(8)], 141.7 [C(7')], 149.46 [C(4)], 152.15 [C(4')], 154.06 [C(2)], 
155.0 [C(6)]. Mass spectrum (FAB) calculated for Ct2Ht4N60 m/z [M+·]: 258; Found: 
[258+1]+·. Anal Calcd. for Ct2Ht4N60: C, 55.80; H, 5.46; N, 32.54. Found: C, 
55.53; H, 5.55; N, 32.20. 
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Method B: A mixture of chloride 77 (0.400 g, 2.024 mmol), freshly distilled (bp 
143-145.C) 2-furfurylamine (114, 0.216 g, 2.23 mmol), and pyridine (9 mL) was placed 
in a similar system as above. The mixture was heated at reflux (2.5 h) with stirring. A 
precipitate was observed almost immediately. The mixture was cooled to room 
temperature over a period of 40 minutes and filtered. The filtrate was evaporated to 
dryness (<45.C) under reduced pressure (2.5 mm Hg) to give a pale yellow solid. Traces 
of pyridine were co-evaporated with benzene (3 x 2 mL). The residue was dissolved in a 
minimum amount of (HCCl3:H3COH; 15:1) and applied to a Chromatotron plate which 
was eluted with the same solvent system. The fraction with an Rr value of 0.30 was 
collected, and the solvent was evaporated (<45.C) to give an off-white solid which was 
washed with ether and dried in vacuo (80.C/5 mm Hg); recrystallization (HCCh) gave 
white needles (0.116 g, 20%) of 89. 
9-(2'-(N-3-Methylpyridinyl)aminomethyi)-N6-bis(phenoxy)phosphin-
yladenine (90). A mixture of chloride 79 (2.00 g, 4.368 mmol), freshly distilled (bp 
73-74.C/1 mm Hg) 3-(aminomethyl)pyridine (111, 0.7085 g, 0.65 mL, 6.6 mmol), and 
pyridine (35 mL) was placed in a 2-necked, 50 mL, round-bottomed flask equipped with a 
condenser, a magnetic stirrer and a gas inlet The mixture was heated at reflux (2.5 h) with 
stirring. The new mixture was cooled to room temperature over a period of 50 min and 
filtered. The filtrate was evaporated to dryness ( <45°C) under reduced pressure (2.5 mm 
Hg) to give an orange solid. Traces of pyridine were co-evaporated with benzene (3 x 1 
mL). The residue was dissolved in a minimum amount of (HCCl3:H3COH; 15:1) and 
applied to a Chromatotron plate which was eluted with the same solvent system. The 
appropriate fraction (2nd band) was collected, and the solvent was evaporated to give a 
yellow oil. This oil was further purified by passing through another plate and eluting with 
a solvent mixture of (HCCl3:H3COH; 25:1). The major fraction was collected and the 
solvent was evaporated to give a colorless oil which upon drying under reduced presure (1 
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mm Hg/RT) gave a foamy solid which was recrystallized (HCCl3:ether; 5:20) by the 
diffusion method. A white solid of 90 was isolated (24 mg, 11 %); mp 59.4-60.5°C. IR 
(HCCl3) 1590-1610 (C=C, C=N), 1195 (C-0) cm-1. lH NMR (DCCl3): 8 3.04 [t, 2 H, 
H(2')], 3.76 [s, 2 H, H(3')], 4.26 [t, 2 H, H(l')], 7.09-7.29 [m, 11 H, Ar-H, and 
H(5')], 7.53 [d, 1 H, H(6')], 7.99 [s, 2 H, H(2) and H(8)], 8.42-8.49 [m, 2 H, H(7') 
and H(8')], 8.68 (s, 1 H, NHP); Be NMR (DCCl3) ppm 44.15 [C(2')], 47.81 [C(l')], 
50.58 [C(3')], 120.60 [C(5)], 122.33 [C(5')], 134.90 [C(6')], 135.75 [C(4')], 144.16 
[C(8)], 148.54 [C(7')], 149.55 [C(8')], 150.25 [C(4')], 151.06 [C(2)]; Ar-C: 120.66, 
125.35, 129.65, 150.30, 151.2, 151.98; 31p NMR (DCCl3; 85% H3P04 external 
reference) ppm -8.77. Mass spectrum (FAB) calculated for C2sH24N703P m/z [M+·]: 
501; Found: [501+1]+·. Anal. Calcd for C25H24N703P·4 H20: N, 17.09; P, 5.40. 
Found: N, 17.09; P, 5.17. We also compared the analysis when 1-3 equivalents of H20 
were incorporated in the sample. Anal. Calcd for C2sH24N703P·3H20: N, 17.64; P, 
5.57; for C25H24N703P·2H20: N, 18.24; P, 5.76; and for C2sH24N703P·H20: N, 
18.87; P, 5.96. 
9-(2'-(N -4-Methyl pyri dinyl)aminomethyi)-N'-bis( 4-tolyl) p hosphinyl-
adenine (91). A mixture of chloride 80 (0.150 g, 0.3276 mmol), freshly distilled (bp 
2300C) 4-(aminomethyl)pyridine (112, 0.0389 g, 0.036 mL, 0.36 mmol), and pyridine (5 
mL) was placed in a 2-necked, round-bottomed flask equipped with a condenser, a 
magnetic stirrer, and a gas inlet. The mixture was heated at reflux (2.5 h) with stirring. 
The new mixture was cooled to room temperature over a period of 50 min and filtered. 
The filtrate was evaporated to dryness ( <45oC) under reduced pressure (2.5 mm Hg) to 
give an orange solid. Traces of pyridine were co-evaporated with benzene (3 x 1 mL). 
The residue was dissolved in a minimum amount of (HCCl3:H3COH; 15:1) and applied to 
a Chromatotron plate which was eluted with the same solvent system. The appropriate 
fraction (2nd band) was collected, and the solvent was evaporated to give a yellow oil. 
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This oil was further purified by passing through another plate and eluting with a solvent 
mixture of (HCCl3:H3COH; 25:1). The major fraction was collected and the solvent was 
evaporated to give a colorless oil which upon drying under reduced presure (1 mm Hg/RT) 
gave a foamy solid which was recrystallized (HCCl3:ether; 3:25) by the diffusion method. 
A white solid of91 was isolated (24 mg, 14%); mp 71-72°C. IR (HCCl3) 3350 (broad, 
N-H), 1610 (C=C), 1198 (C-0) cm-1. lHNMR (DCCl3): o 2.23 [s, (2 CH3), and NH], 
3.07 [t, 2 H, H(2')], 3.79 [s, 2 H, H(3')], 4.32 [t, 2 H, H(1')], 7.00-7.27 [m, 9 H, Ar-
H, and H(5')], 8.04 and 8.05 [both s, 2 H, H(2) and H(8)], 8.47 [d, 2 H, H(6')], 8.69 
(s, 1 H, NHP); 13C NMR (DCCl3) ppm 19.90 (2 CH3), 43.39 [C(2')], 47.30 [C(l')], 
51.29 [C(3')], 120.08 [C(5)], 122.07 [C(5')], 142.98 [C(8)], 147.29 [C(4')], 148.02 
[C(4)], 148.95 [C(6')], 151.17 [C(2)]; Ar-C: 119.43, 119.47, 129.34, 129.38, 134.18, 
150.33; 31p NMR (DCCl3; 85% H3P04 external reference) ppm -9.233. Mass spectrum 
(FAB) calculated for C27H2sN703P m/z [M+·]: 529; Found: [529+ 1]+·. Anal. Calcd for 
C27H2sN703P·H20: N, 17.91; P, 5.66. Found: N, 17.94; P, 5.32 
Attempted Preparation of 9-(2'-(N -4-Methylpyridinyl)aminomethyi)-
N'-bis(4-tolyl)phosphinyladenine (91) in Et3N/n-Butanol. In a 2-necked, 
round-bottomed flask (50 mL) equipped with a condenser and a gas inlet was placed 
freshly distilled 4-(aminomethyl)pyridine (112, 0.0377 g, 0.384 mmol), triethylamine 
(0.058 mL, 0.4188 mmol), and freshly distilled n-butanol (5 mL). The reaction mixture 
was stirred at room temperature for 15 min. To this mixture was added chloride 80 (0.150 
g, 0.349 mmol) in one portion, and the mixture was allowed to heat at reflux for 5 h. The 
reaction mixture was cooled to room temperature over a period of 1 h, during which time 
no precipitate was observed. The solvent was evaporated to give a dark red syrup which 
was applied to a Chromatotron plate and eluted with a solvent mixture of (HCCl3:H3COH; 
15:1). The only isolable band was collected and identified as starting material. 
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Attempted Phosphorylation of (85) with (PhO)lP(O)CI (94b). In a 3-
necked, 50 mL, round-bottomed flask equipped with a condenser, a gas inlet, and a 
magnetic stirrer was placed amine 85 (0.10 g, 0.371 mmol), and pyridine (3 mL). The 
reaction mixture was allowed to heat under reflux for 2 min, and then diphenyl 
chlorophosphate (94b, 0.109 g, 0.371 mmol), was added dropwise over a period of 8 
min. A color change was observed from yellow to dark brown within the first 8 min. 
After heating the reaction mixture at reflux for 40 min, the mixture was cooled to room 
temperature over a period of 90 min. Evaporation of pyridine gave a dark brown oil, 
which upon analysis with TLC (HCCl3:H3COH; 20:2) showed two spots one of which 
corresponds to starting material compound 85. The other spot appeared at the baseline 
and was considered to be the phosphorus starting material, based on the TLC analysis of a 
pure sample of the starting material. 
Attempted Cyclization of the Diaminopyrimidine 119 in Et3 NIT H F 
(Preparation of 92). In a 2-necked, 25 mL, round-bottomed flask equiped with a · 
condenser and a magnetic stirrer was placed the diamine 119 (0.150 g, 0.5865 mmol), dry 
THF (8 mL), and triethylamine (0.33 mL, 2.346 mmol). The mixture was stirred 
vigorously until all the solid material dissolved. To this mixture was added dropwise a 
solution of phenyl dichlorophosphate (104, 0.1237 g, 0.5865 mmol) in dry THF (1 
mL) via a needle. The mixture was stirred at room temperature for 24 h, during which 
time the reaction progress was monitored by TLC (HCC13:H3COH; 10:1). The mixture 
was filtered and the filtrate was evaporated to give a dark purple syrup. The syrup was 
dissolved in a minimum amount of HCCl3 and the solution was applied to a Chromatotron 
plate, which was eluted with a solvent mixture of (HCCl3:H3COH; 12:3). The appropriate 
fraction (2nd band) was collected and the solvent was evaporated to give a yellow syrup. 
This syrup was further purified by passing it through another identical Chromatotron plate 
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and eluting with a solvent mixture of (HCCl3:H3COH; 10: 1). The major fraction was 
collected and evaporated to give a light brown oil which upon drying under reduced 
pressure (RT/1 mm Hg) gave a foamy solid which was recrystallized (HCCl3:ether; 5:20) 
by the diffusion method. A lihgt orange solid of 92 was isolated (22 mg, 14.3%); mp 
101.5-103°C. IR (KBr) 3500-3200 (broad, 0-H, HN-H), 1555-1625 (C=C, C=N), 1255 
(P=O), 1205 (C-0) cm-1. lH NMR (DMSO-d6) o 1.38-1.41 [m, 2 H, (CHH)], 2.44-
2.48 [m, 2 H, (CHH)], 2.95-2.98 [m, 2 H, H(4')], 4.06-4.15 [m,.4 H, H(6')], 5.04-
5.09 [m, 2 H, H(1')], 5.30-5.60 (broad, 4 H, 2 NH2), 5.83-5.87 [m, 4 H, (CH=CH)], 
6.80 (d, 2 H, 2 OH), 7.20-7.42 (m, 5 H, Ar-H); 13C NMR (DMSO-d6) ppm 33.79 
[C(5')], 44.61 [d, C(4'), 4JP-C = 7.2 Hz], 56.19 [C(l')], 70.93 [d, C(6'), 2Jp_c = 5.8 
Hz], 113.43 [C(5)], 132.65 and 134.04 (CH=CH), 150.08 (C-0-P), 154.06 [C(6)], 
154.71 [C(2)], 119.82, 119.86, 125.09, 129.82 (Ar-C); 31p NMR (DMSO-d6; 85% 
H3P04 external reference) ppm -6.48. Mass spectrum (FAB) calculated for 
C26H31Ci2N1004P m/z [M+·]: 648; Found: [648+1]+·. Anal. Calcd for 
C26H31ChNw04P·3H20: N, 19.91; P, 4.40. C26H31CbNw04P·2.5H20: N, 20.16; 
P, 4.43. Found: N, 19.51; P, 4.83. For 92 with mp 102.3-103.2; Found: N, 19.84; P, 
4.96. The best fit is with three H20 equivalents present. 
Phenyl Phenylphosphonochloridate (105).49 A mixture of freshly distilled 
phenol (3.764 g, 0.040 mol) and PhP(O)Ch (103, 7.8 g, 0.04 mol) was heated (24) at 
1500C in a jacketed flask equipped with a condenser and gas inlet using boiling xylene. 
The mixture was cooled to room temperature and then distilled. The first fraction was 
discarded but the fraction boiling at 166-170°C/2.5 mm was a colorless oil (5.5 g, 54%; 
lit49 bp 92-98°C/0.3 mm Hg, 59%). lH NMR (DCCl3) o 7.2-8.1 (m, Ar-H); 13C NMR 
(DCCl3) ppm 120.8, 126.0, 128.8, 128.9, 129.7, 129.6, 129.9, 131.2, 131.3, 131.4, 
133.9, 149.6 (d, C-0-P, 2JP-C = 10.7 Hz). 31p NMR (DCCl3; 85% H3P04) ppm 
+26.38. The lH NMR and Be NMR spectral data have not been previously reported. 
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(+)-cis- [ 4- [ (2,5-Diamino-6-chloro-4-pyrimi diny l)amino ]-2-cyclopent-
enyl] carbinol (119).81 A mixture of alcohol125 (3.83 g, 0.01 mole), zinc dust 
(6.604 g, 0.1 mole), acetic acid (3.23 mL), water (151 mL) and ethanol (151 mL) was 
heated under reflux for 3 h in a 3-necked, round-bottomed flask (1000 mL) equipped with 
a condenser and a magnetic stirrer. After cooling to room temperature over a period of 2 h, 
the reaction mixture was filtered and the solvents were evaporated. The residue (a brown 
solid) was absorbed on silica gel and applied to a column (silica gel) which was then eluted 
with a solvent system of eHel3:H3eOH (20:1). The fractions with an Rr value of 0.32 
were collected, and the solvent was evaporated to give a purple solid 119 (1.42 g, 55%; 
1it81 66%), mp 169-170oe (lit81 mp 168-1700e). lH NMR (DMSO-d6) () 1.38 (q, 1 H, 
eHH), 2.43 (m, 1 H, eHH), 2.75 (m, 1 H, H(4')], 3.40 [d, 2 H, H(6')], 4.55 (bs, 2 H, 
NHz), 5.08 [m, 1 H, H(1')], 5.76-5.89 (eH=eH), 6.49 (d, 1 H, OH or NH), 8.2 (s, 1 
H, OH or NH). Be NMR (DMSO-d6) ppm 34.40 [e(S')], 47.22 [e(4')], 56.16 [e)1')], 
64.79 [e(6')], 113.41 [e(5)], 132.65, 134.86 (CH=CH), 154.47 [e(2)], 155.28 [e(6)], 
[e(4), was not observed]. Mass spectrum (EI, 70 eV) calculated for etoH14elNsO m/z 
[M+·]: 255 and 257; Found: 255 and 257 [M+ and M+ +2]. The lH NMR and the Be 
NMR spectral data have not been previously reported. 
Attempted Cyclization of the Diaminopyrimidine 119 in Bromobenzene . 
. 
In a 2-necked, 50 mL, round-bottomed flask equipped with a condenser and a magnetic 
stirrer was placed the diamine 119 (0.2126 g, 0.832 mmol), phenyl dichlorophosphate 
(104, 0.351 g, 1.664 mmol), and bromobenzene (10 mL). The reaction mixture was 
stirred for 10 min during which time the mixture became yellow. The reaction mixture was 
then heated under reflux for (2 h). TLe analysis (Hee13:H3eOH; 10: 1) of this mixture 
did not indicate the presence of only starting material. The reaction mixture was allowed to 
heat under reflux for an additional (3 h) which resulted in the formation of a dark solution. 
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It was also noted that no product had formed during this time as indicated by TLC 
(HCCl3:H3COH; 10: 1) analysis. The procedure employed was similar in nature to 
conditions previously cited in the literature20 for the reaction of o-phenylenediamine with 
phenyl dichlorophosphate. 
Attempted Cyclization of the Diaminopyrimidine 119 in Pyridine. In a 2-
necked, 50 mL, round-bottomed flask equipped with a condenser and a magnetic stirrer 
was placed the diamine 119 (0.100 g, 0.391 mmol) and pyridine (6 mL). To this mixture 
was added, phenyl dichlorophosphate (104, 0.0825 g, 0.43 mmol) dropwise over a 
period of 5 minutes. The reaction mixture was stirred at room temperature for 3 h, and the 
reaction was followed by TLC (HCCl3:H3COH; 10:1)) which indicated no change relative 
to that of the TLC at time zero. The mixture was allowed to stir at room temperature for an 
additional 12 h; the TLC of this mixture did not indicate the appearance of any new 
material. The reaction mixture was then heated at reflux for 6 h, but TLC analysis again 
did not indicate any product. Some starting material was detected, but a dark residue did 
not move on the TLC plate. 
Attempted Cyclization of the Diaminopyrimidine 119 in Et3N/Toluene. 
In a 2-necked, 50 mL, round-bottomed flask equiped with a condenser and a magnetic 
stirrer was placed the diamine 119 (0.2126 g, 0.832 mmol), dry toluene (6 mL), and 
triethylamine (0.35 mL, 1.664 mmol). To this mixture was added dropwise a solution of 
phenyl dichlorophosphate (104, 0.351 g, 1.664 mmol) in dry toluene (4 mL) through a 
needle, and the reaction mixture was heated under reflux for 4 h. The mixture was cooled 
to room temperature and filtered. The filtrate was evaporated to give a dark brown syrup, 
which was applied to a Chromatotron plate and eluted with a solvent mixture of 
(HCCl3:H3COH; 10: 1). The only isolated band was collected; solvent was evaporated 
and the residue was dried under vacuum. 1 H NMR analysis of this material indicated it to 
98 
be starting material. The procedure employed was similar in nature to conditions 
previously cited in the literature59 for the reaction of 2,2'-methylenebis(4-chlorophenol) 
with phenyl dichlorophosphate. 
2-Azabicyclo[2.2.1]hept-5-en-3-one (121).19 Cyclopentadiene was freshly 
distilled (bp 40-41 o C) using a vigreux column and an ice-cooled receiver. In a single 
necked, round-bottomed flask (500 mL) was placed Ts-CN (30.0 g, 0.1655 mol, Aldrich) 
and cyclopentadiene (168 g, 2.6 mol, 210 mL). The reaction was allowed to stir at room 
temp for 35 min. The mixture was evaporated to dryness (45 min) without heating using 
an aspirator. The residue was cooled in cold water and swirled while cooled glacial acetic 
acid (53 mL) was added rapidly to the flask. The resulting mixture was then poured 
rapidly into ice-water (200 g). The mixture was filtered through a thick celite pad (using a 
frit funnel), and the pad was washed with additional water (80 mL). The filtrate-wash was 
cooled in cold water and stirred while cold 12 N sodium hydroxide was added dropwise to 
pH 8. This solution was saturated with sodium chloride (a large amount was needed, 
about 45 g) and then extracted with H2CCl2 (3 x 200 mL). One additional extraction was 
carried out by allowing the mixture to stir vigorously overnight with 200 mL of H2CCI2. 
All extracts were combined and dried (MgS04, overnight). Filtration followed by 
evaporation ( 45°C/30 mm Hg) of the solvent gave a brown oil (12.3 g) which was purified 
by distillation (bp 90-94 o C/0.1 mm Hg) to give the product which solidified upon standing 
to solid 121 (8.6 g, 49%); mp 50-52°C, (litl9 mp 50-52°C). lH NMR (DC03): B 2.20 
(dt, 1 H, J = 8 and 2 Hz, CHH), 2.39 (dt, 1 H, J = 8 and 2 Hz, CHH), 3.2 (m, 1 H, 
CHC=O), 4.4 (m, 1 H, CHN), 6.6-6.8 (m, 2 H, CH=CH), 6.5 (br, 1 H, NH). These 
spectral data (lH NMR) are identical with those reported.19 
Methyl cis-4-Acetamidocyclopent-2-enecarboxylate (122).19 Compound 
121 (8.6 g, 0.0788 mol) was dissolved in 5% hydrochloric acid (340 mL), and the 
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solution was stirred at room temp for 3.5 days in a single-necked, round-bottomed flask 
(1000 mL). Then 6 N sodium hydroxide (30 mL) was added (with cooling, in an ice bath) 
to pH 1.0 (using a pH meter). The solution was evaporated to dryness ( < 50 ° C) in vacuo 
(0.1 mm Hg). The residue was azeotroped with benzene-methanol (50:50) for 5 h, dried, 
and then boiled in dry methanol (140 mL-HPLC grade) for 18 h in a Dean-Stark setup. 
The sodium chloride was filtered off and washed with additional methanol (25 mL). The 
combined washing and filtrate were evaporated to dryness, and the residual semi-solid was 
dissolved in pyridine (67mL) and cooled in an ice bath. Acetic anhydride (41 mL, freshly 
distilled) was added in portions over 12 min, and the solution was allowed to come to 
room temperature (45 min). After an additional 1 h, the solvent was evaporated to 
dryness. The residue was dissolved in H2CCl2 (70 mL); the solution extracted with 
saturated NaHC03 (4 x 27 mL) and washed with saturated NaCl (7 mL). After drying 
(MgS04, 10 h), the solution was filtered and evaporated to give a brown syrup which was 
co-evaporated with toluene (3 x 27 mL) to remove pyridine. Upon standing for 1 h, the 
solution solidified to a pale brown solid which weighed 12.03 g. The product was 
purified by sublimation (65-80 ° C/0.05 mm Hg) to give a white powder of 122 (10.9 g, 
75%, lit19 89%); mp 66-67°C, (lit19 mp 66-6TC). lH NMR (DCCl3) 5 1.86-1.92 (dt, 1 
H, CHH, J = 10.75 and 3.31 Hz), 1.97 (s, 3 H, C(O)CH3), 2.47 (dt, 1 H, CHH, J = 8 
and 5.6 Hz), 3.49-3.5 (m, 1 H, CHC02Me), 3.72 (s, 3 H, OCH3), 5.08 (m, 1 H, CHN), 
5.89 (m, 2 H, CH=CH), 6.1 (bs, 1 H, NH). These spectral (lH NMR) data are identical 
with those reported.31 
cis-4-Acetamidocyclopent-2-enemethyl Acetate (123).19 In a single-neck, 
round-bottomed flask (1000 mL) equipped with a condenser and a gas inlet was place a 
mixture of calcium chloride (8.987 g, 0.081 mol) and sodium borohydride (6.126 g, 
0.162 mol) in THF (170 mL), and the mixture was allowed to stir at room temp for 1 h. 
This mixture was milky with the presence of a fine, solid precipitate. A solution of ester 
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122 (9.80 g, 0.054 mol) in THF (140 mL) was added all at once. The resulting mixture 
was stirred at room temp for-18 h. It was then cooled in an ice bath, and ice-water (200 
mL) was added dropwise. Cold 6 N hydrochloric acid (90 mL) was then added (to pH 
1.5), and the resulting clear solution was stirred at room temperature for 1 h. This solution 
was evaporated in vacuo (40°C/2.5 mm Hg), and the residue was co-evaporated with 
methanol (4 x 140 mL) and with pyridine (2 x 140 mL) to give a yellow semi-solid. 
Pyridine (70 mL) was added and the insoluble inorganics were filtered off. Acetic 
anhydride (70 mL) was added to the filtrate, and the mixture was stirred at room temp for 
18 h. After evaporation (60°C/40 mm Hg) of volatile materials, methanol (70 mL) was 
added, and the mixture was heated with stirring under reflux for 10 min. Methanol was 
evaporated and the residue was stirred with HzCClz (140 mL)-water (70 mL) while solid 
sodium bicarbonate was added cautiously until the aqueous layer became basic (pH ""' 8). 
The layers were separated and the aqueous layer was extracted with HzCClz (2 x 70 mL). 
The combined organic layers were dried (MgS04, 10 h)) and evaporated. The residue was 
azeotroped with toluene (3 x 70 mL) leaving an orange oil (9.8 g). Distillation (bp 120-
12( C/0.03 mm Hg) of this oil gave a pale yellow syrup 123 which solidified in the 
refrigerator (8.8 g, 81%, Iit19 98%]; mp 61.5-62.5°C, (lit19 mp 62-63°C). IR (neat) 3270 
(br, N-H), 3055 (HC=CH), 1740 (OAc) cm-1. 1H NMR (DCC13) () 1.30 [dt, 1 H, 
(CHH)], 1.95 and 2.05 (both s, 6 H, H3CCOz and H3CCON), 2.49 [dt, 1 H, (CHH)], 
2.97 [m, 1 H, H(4)], 4.04 [m, 2 H, (CHzO)], 5.0 (m, 1 H, CHN), 5.80 (m, 2 H, 
CH=CH) 5.95 (bs, 1 H, NH). These data are identical with those reported.31 Be NMR 
(DCCl3) ppm 20.95 (NHC(O)CH3), 23.30 (OC(O)CH3), 34.98 (CHz), 43.85 [C(4)], 
54.85 (CHN), 67.41 (CH20H), 133.28, 134.23 (CH=CH), 169.40, 170.98 [NC(O), 
OC(O)]. The1H NMR and Be NMR spectra have not been previously reported. 
(+)-cis- [ 4- [ (2-Amino-6-chloro-4-pyrimidinyl)amino ]-2-cyclo pentenyl]-
carbinol (124).81 A mixture of ester 123 (7.50 g, 0.038 mole) and Ba(OH)2 (0.5 N, 
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300 mL) was heated under reflux overnight in a 3-necked, round-bottomed flask (1000 
mL) equipped with a condenser and a gas inlet. After cooling to room temperature (3 h), 
the brown mixture was neutralized with dry ice and filtered. The filtrate was evaporated 
(50°C/2.5 mm Hg) to give a yellow semi-solid residue which was exrtacted with ethanol 
(anhydrous) (4 x 50 mL). Evaporation of the solid gave a light yellow syrup to which was 
added 2-amino-4,6-dichloropyrimidine (9.225 g, 0.0562 mole), triethylamine (15.88 g, 
0.157 mole) and freshly distilled n-butanol (150 mL), and this mixture was heated under 
reflux for 48 h. The resulting mixture was cooled to room temperature and the volatile 
solvents were evaporated to give a brown semi-solid which was absorbed on silica gel (28 
g) and packed into a column which was eluted with (eHel3:H3eOH, 40:1, 30:1). The 
fractions with an Revalue of 0.32 were collected, and the solvent was evaporated to give a 
yellow syrup which, upon drying at reduced pressure (0.1 mm Hg), gave a foamy white 
solid. Some fractions from the column contained two spots on the TLe plate (one of 
which was on the base line); these fractions were evaporated to give a yellow syrup. To 
this syrup was added a small amount of acetone (3 mL) to precipitate triethylamine. 
Filtration and evaporation of the solvent gave a yellow syrup which, upon drying at 
reduced pressure (0.1 mm Hg), gave a white foamy solid. The obtained solids were 
combined to give 124 (6.22 g, 68%, 1it81 76% ); mp 134-135.5oe, (1it81 mp 132-134oe). 
lH NMR (Deel3) o 1.45-1.52 (dt, 1 H, eHH), 2.43-2.53 (m, 1 H, CHH), 2.87 [bd, 1 
H, H(4')], 3.54-3.68 (m, 2 H, eHzO), 4.75-5.70 (three broad s, NH, NHz and OH), 
5.76-5.91 (m, 2 H, CH=eH), (the eHN proton signal is probably buried under broad 
signals of NH, NH2 or OH); Be NMR (Deel3) ppm 34.29 [C(5')], 46.88 [e(4')], 56.4 
(CHN), 64.1 (CHzO), 132.4, 134.5 (CH=CH), 162.3, 163.1 (carbons from pyrimidine 
ring). Mass spectrum (EI, 70 eV) calculated for e10HBelN40 m/z [M+·]: 240 and 242; 
Found: 240 and 242 [M+ and M+ + 2]. The Be NMR spectra have not been previously 
reported. 
102 
(+)-cis- [ 4- [2-Amino-6-chloro-5- [ ( 4-chlorophenyl)azo ]-4-pyrimidinyl]-
amino]-2-cydopentenyl]carbinol (125).81 The diazonium salt was prepared as 
follows. A solution of p-chloroaniline (2.424 g, 0.019 mole) in 3 N HCl (40.4 mL) was 
added to an ice cooled solution of sodium nitrite (1.43 g, 0.021 mole) in H20 (16.6 mL). 
This new cooled solution was added to a mixture of alcohol124 (3.95 g, 0.0164 mole), 
acetic acid (83 mL), H20 (83 mL) and sodium acetate trihydrate (33.2 g, 0.244 mole) in a 
single-necked, round-bottomed flask (500) mL. This mixture was stirred overnight at 
room temperature to give a yellow orange solution. The yellow/orange precipitate was 
filtered and washed with cold water until the filtrate became neutral. The precipitate was 
air dried for 36 h in a fume hood to give an orange solid 125 which was recrystallized 
(acetone:H3COH; 1:2), (5.7 g, 92%; 1it81 94%), mp 230oC dec (lit81 229°C dec). lH 
NMR (DMSO-d6) B 1.51 (dt, 1 H, CHH), 2.47 [m, 1 H, CHH), 2.78 (bs, 1 H, H(4')], 
3.34 (1 H, NH or OH), 3.40 (t, 2 H, CH20H), 4.8 (t, 1 H, CHN), 5.25 (bs, 1 H, NH or 
OH), 5.83-5.96 (m, 2 H, CH=CH), 7.55-7.73 (m, 6 H, ArH and NH2). 13C NMR 
(DMS0-d6) ppm 33.8 (CH2), 47.2 [C(4')], 55.1 (CHN), 63.90 (CH20H), 118.2 [C(5)], 
133.2, 136.4 (CH=CH), 153.5 [C(2)], 160.9 [C(6)], 164.8 [C(4)], [122.7, 129.3, 131.3 
(Ar-C)]. ThelH NMR and Be NMR spectra have not been previously reported. 
Attempted Cyclization of 4,5,6-Triaminopyrimidine Hydrosulfate (116) 
With (PhO)JP. In a 2-necked, 50 mL, round-bottomed flask equipped with a magnetic 
stirrer and a micro distillation apparatus with an Argon inlet was placed 4,5,6-
triaminopyrimidine hydrosulfate (116, 0.400 g, 1.79 mmol) and triphenyl phosphite 
(1.140 g, 1.79 mmol). The mixture was heated in a sand bath (150-180°C) while stirring 
under reduced pressure (1 mm Hg) until distillation of phenol has completely ceased (0.95 
mL). The reaction mixture was cooled to room temperature and a brown residue was 
observed in the flask. The residue was triturated with hot xylene (3 x 10 mL) and filtered. 
This precipitate was washed with HCCl3 (3 x 10 mL) and ethanol (3 x 10 mL). All 
103 
attempts to recrystallize or purify the isolated solid failed (including sublimation and 
chromatography). The procedure employed was similar in nature to conditions previously 
cited in the literature41 for the reaction of 4,5-diaminopyrimidine with triphenyl phosphite 
which was claimed to give the compound 118 shown below on the bases of mp (360°C) 





The 31p NMR analysis of the crude product obtained from our reaction revealed a large 
number of signals, indicating a severe mixture had formed. 
Attempted Cyclization of 4,5,6-Triaminopyrimidine (115) with (PhO )JP. 
4,5,6-Triaminopyrimidine hydrosulfate (116, 1 g, 4.48 mmol) was dissolved in NaOH 
(10%, 40 mL), and the solution was heated to 70-75oC in a water bath with stirring. The 
solution was cooled to room temperature over a period of 1 h and then chilled in an ice bath 
(2 h) to give yellow needles (yields ranged from 70-90% ). The product was further 
purified by sublimation (100-120°C/0.75 mm Hg) to give a white powder of 4,5,6-
triaminopyrimidine (115), mp 252-254oC (lit15 mp 255-257°C). 
In a 2-necked, round-bottomed flask equipped with a magnetic stirrer and a micro 
distillation apparatus with an argon inlet was plac_ed the amine 4,5,6-triaminopyrimidine 
(115, 0.200 g, 1.598 mmol) and triphenyl phosphite (0.496 g, 1.6 mmol). The mixture 
was heated in a sand bath (90-100°C) while stirring under reduced pressure (1 mm Hg). It 
was noticed that after 2 h the reaction mixture turned to a tar-like residue which was 
intractable. The procedure was similar in nature to conditions previously cited in the 
literature41 for the reaction of 4,5-diaminopyrimidine with triphenyl phosphite. 
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Attempted Cyclization of 4,5,6-Triaminopyrimidine (115) with PCI3. In 
a 3-necked, 50 mL, round-bottomed flask equipped with a condenser and a magnetic 
stirrer was placed 4,5,6-triaminopyrimidine (115, 0.300 g, 2.4 mmol) and bromo benzene 
(9 mL). The mixture was heated to tto•c in an oil bath. To this mixture was added 
dropwise a solution of phosphorus chloride (0.33 g, 0.21 mL, 2.4 mmol) in 
bromobenzene (3 mL). The reaction mixture was heated at llO"C (8 h) during which time 
the reaction mixture became solid. This solid was washed with bromobenzene (20 mL), 
hexane (20 mL) and dried under vacuum to give a brown solid, which could not be 
separated into its components by recrystallization, chromatography, or sublimation. 
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